DeferredTaxAssetsDeferredIncome

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2022~~2023

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File Number: 001-37477

TELADOC HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware		04-3705970
(State of incorporation)		(I.R.S. Employer Identification No.)

2 Manhattanville Road, Suite 203
Purchase, New York		10577
(Address of principal executive office)		(Zip code)

(203) 635-2002

(Registrant’s telephone number including area

code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TDOC	The New York Stock Exchange

Indicate by check mark whether the ~~registrant:~~registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated ~~filer”,~~filer,” “smaller reporting ~~company”~~company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:


Large accelerated filer	⌧	Accelerated filer	◻	Non-accelerated filer	◻	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange ~~Act.)~~Act). Yes ☐ No ⌧

As of April ~~27, 2022,~~26, 2023, the Registrant had ~~161,182,633~~163,670,601 shares of Common Stock outstanding.

Table of Contents

TELADOC HEALTH, INC.

QUARTERLY REPORT ON FORM 10-Q

For the period ended March 31, ~~2022~~2023

TABLE OF CONTENTS

		Page Number

PART I	Financial Information	2
Item 1.	Financial Statements	2
	Condensed Consolidated Balance Sheets as of March 31, ~~2022~~2023 (unaudited) and December 31, ~~2021~~2022	2
	Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the quarters ended March 31, ~~2022~~2023 and ~~2021~~2022	3
	Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the quarters ended March 31, ~~2022~~2023 and ~~2021~~2022	4
	Condensed Consolidated Statements of Cash Flows (unaudited) for the ~~three months~~quarters ended March 31, ~~2022~~2023 and ~~2021~~2022	5
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2223
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	32
PART II	Other Information	33
Item 1.	Legal Proceedings	33
Item 1A.	Risk Factors	33
Item 6.	Exhibits	34
Exhibit Index		34
Signatures		3635

Table of Contents

PART I

FINANCIAL INFORMATION

ITEM 1. Financial Statements

TELADOC HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data, unaudited)


	March 31,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Assets
Current assets:
Cash and cash equivalents	$	836,444	$	893,480	$	888,579	$	918,182
Short-term investments		2,544		2,537
Accounts receivable, net of provision of $13,056 and $12,384, respectively		191,528		168,956
Accounts receivable, net of allowance for doubtful accounts of $6,106 and $4,324, respectively						215,981		210,554
Inventories		70,654		73,079		45,801		56,342
Prepaid expenses and other current assets		106,875		87,387		136,346		130,310
Total current assets		1,208,045		1,225,439		1,286,707		1,315,388
Property and equipment, net		28,419		27,234		29,791		29,641
Goodwill		7,899,795		14,504,174		1,073,190		1,073,190
Intangible assets, net		1,883,897		1,910,278		1,815,948		1,836,765
Operating lease - right-of-use assets		45,552		46,780		39,518		41,831
Other assets		26,629		20,703		63,993		48,540
Total assets	$	11,092,337	$	17,734,608	$	4,309,147	$	4,345,355
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	47,412	$	47,257	$	38,625	$	47,690
Accrued expenses and other current liabilities		116,689		102,933		184,642		168,693
Accrued compensation		46,075		91,941		50,900		81,554
Deferred revenue-current		83,847		75,569		95,930		90,457
Advances from financing companies		12,664		13,313		11,247		11,375
Total current liabilities		306,687		331,013		381,344		399,769
Other liabilities		1,445		1,492		1,749		1,618
Operating lease liabilities, net of current portion		40,163		41,773		35,927		38,042
Deferred revenue, net of current portion		2,884		3,834		4,117		3,872
Advances from financing companies, net of current portion		8,252		9,291		8,037		8,082
Deferred taxes, net		57,516		75,777		50,613		50,939
Convertible senior notes, net		1,532,780		1,225,671		1,536,134		1,535,288
Commitments and contingencies (Note 10)
Commitments and contingencies (Note 12)
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 161,434,513 shares and 160,469,325 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively		161		160
Common stock, $0.001 par value; 300,000,000 shares authorized; 163,919,394 shares and 162,840,360 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively						164		163
Additional paid-in capital		17,177,152		17,473,336		17,409,574		17,358,645
Accumulated deficit		(8,023,279)		(1,421,454)		(15,077,515)		(15,008,287)
Accumulated other comprehensive loss		(11,424)		(6,285)		(40,997)		(42,776)
Total stockholders’ equity		9,142,610		16,045,757		2,291,226		2,307,745
Total liabilities and stockholders’ equity	$	11,092,337	$	17,734,608	$	4,309,147	$	4,345,355

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

TELADOC HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data, unaudited)


	Quarter Ended March 31,				Quarter Ended March 31,
	2022		2021		2023		2022
Revenue	$	565,350	$	453,675	$	629,244	$	565,350
Expenses:
Cost of revenue (exclusive of depreciation and amortization, which is shown separately below)		187,025		145,959		190,107		187,025
Operating expenses:
Advertising and marketing		133,600		89,439		176,790		133,600
Sales		58,329		64,793		54,490		58,329
Technology and development		87,412		78,008		86,985		87,412
General and administrative		104,923		105,172		114,145		104,923
Acquisition, integration, and transformation costs		4,507		6,323		5,944		4,507
Restructuring costs						8,102		0
Depreciation and amortization		58,933		48,659		69,783		58,933
Goodwill impairment		6,600,000		0		0		6,600,000
Total expenses		7,234,729		538,353		706,346		7,234,729
Loss from operations		(6,669,379)		(84,678)		(77,102)		(6,669,379)
Loss on extinguishment of debt		0		11,459
Other income, net		(724)		(5,652)		(4,907)		(724)
Interest expense, net		5,480		22,125
Net loss before taxes		(6,674,135)		(112,610)
Income tax expense		388		87,039
Interest (income) expense, net						(3,648)		5,480
Loss before provision for income taxes						(68,547)		(6,674,135)
Provision for income taxes						681		388
Net loss		(6,674,523)		(199,649)		(69,228)		(6,674,523)
Other comprehensive loss, net of tax:
Other comprehensive income (loss), net of tax:
Currency translation adjustment and other		(5,139)		(13,492)		1,779		(5,139)
Comprehensive loss	$	(6,679,662)	$	(213,141)	$	(67,449)	$	(6,679,662)

Net loss per share, basic and diluted	$	(41.58)	$	(1.31)	$	(0.42)	$	(41.58)

Weighted-average shares used to compute basic and diluted net loss per share		160,532,301		152,167,606		162,922,691		160,532,301

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

TELADOC HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data, unaudited)


								Accumulated											Accumulated
				Additional				Other		Total					Additional				Other		Total
	Common Stock			Paid-In		Accumulated		Comprehensive		Stockholders’		Common Stock			Paid-In		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Gain (Loss)		Equity		Shares	Amount		Capital		Deficit		Gain (Loss)		Equity
Balance as of December 31, 2022												162,840,360	$	163	$	17,358,645	$	(15,008,287)	$	(42,776)	$	2,307,745
Exercise of stock options												28,127		0		296		0		0		296
Issuance of common stock upon vesting of restricted stock units												1,050,907		1		(1)		0		0		0
Stock-based compensation												0		0		50,634		0		0		50,634
Other comprehensive income, net of tax												0		0		0		0		1,779		1,779
Net loss												0		0		0		(69,228)		0		(69,228)
Balances as of March 31, 2023												163,919,394	$	164	$	17,409,574	$	(15,077,515)	$	(40,997)	$	2,291,226

Balance as of December 31, 2021	160,469,325	$	160	$	17,473,336	$	(1,421,454)	$	(6,285)	$	16,045,757	160,469,325	$	160	$	17,473,336	$	(1,421,454)	$	(6,285)	$	16,045,757
Cumulative effect adjustment due to adoption of ASU 2020-06 (see Note 2)	0		0		(363,731)		72,698		0		(291,033)
Cumulative effect adjustment due to adoption of ASU 2020-06												0		0		(363,731)		72,698		0		(291,033)
Exercise of stock options	267,586		0		3,585		0		0		3,585	267,586		0		3,585		0		0		3,585
Issuance of common stock upon vesting of restricted stock units	697,602		1		(1)		0		0		0	697,602		1		(1)		0		0		0
Stock-based compensation	0		0		63,963		0		0		63,963	0		0		63,963		0		0		63,963
Other comprehensive loss, net of tax	0		0		0		0		(5,139)		(5,139)	0		0		0		0		(5,139)		(5,139)
Net loss	0		0		0		(6,674,523)		0		(6,674,523)	0		0		0		(6,674,523)		0		(6,674,523)
Balance as of March 31, 2022	161,434,513	$	161	$	17,177,152	$	(8,023,279)	$	(11,424)	$	9,142,610	161,434,513	$	161	$	17,177,152	$	(8,023,279)	$	(11,424)	$	9,142,610


Balance as of December 31, 2020	150,281,099	$	150	$	16,857,797	$	(992,661)	$	18,518	$	15,883,804
Exercise of stock options	1,238,112		1		11,907		0		0		11,908
Issuance of common stock upon vesting of restricted stock units	976,999		1		(1)		0		0		(0)
Issuance of common stock for 2022 Notes	1,058,373		1		270,111		0		0		270,112
Equity portion of extinguishment of 2022 Notes	0		0		(224,081)		0		0		(224,081)
Issuance of common stock for 2025 Notes	1,056,861		1		288,485		0		0		288,486
Equity portion of extinguishment of 2025 Notes	0		0		(237,261)		0		0		(237,261)
Recovery of excess common stock issued for acquisition	(205,280)		(0)		(40,329)		0		0		(40,329)
Stock-based compensation	0		0		90,000		0		0		90,000
Other comprehensive loss, net of tax	0		0		0		0		(13,492)		(13,492)
Net loss	0		0		0		(199,649)		0		(199,649)
Balance as of March 31, 2021	154,406,164	$	154	$	17,016,628	$	(1,192,310)	$	5,026	$	15,829,498

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

TELADOC HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, unaudited)

Quarter Ended March 31,


2022

2021

Operating activities:







Net loss

$
(6,674,523)

$
(199,649)

Adjustments to reconcile net loss to net cash used in operating activities:

Goodwill impairment

6,600,000

0

Depreciation and amortization

58,933

48,659

Depreciation of rental equipment

770

824

Amortization of right-of-use assets

3,173

2,948

Provision for doubtful accounts

4,591

3,074

Stock-based compensation

60,436

86,300

Deferred income taxes

(2,319)

87,004

Accretion of interest

826

16,829

Loss on extinguishment of debt

0

11,459

Gain on sale of investment

0

(5,852)

Other, net

0

38

Changes in operating assets and liabilities:

Accounts receivable

(27,842)

(11,717)

Prepaid expenses and other current assets

(18,993)

(12,799)

Inventory

2,023

(2,877)

Other assets

(6,047)

1,244

Accounts payable

492

(11,989)

Accrued expenses and other current liabilities

11,706

(1,889)

Accrued compensation

(48,819)

(43,624)

Deferred revenue

7,479

17,086

Operating lease liabilities

(3,626)

(3,076)

Other liabilities

(7)

(19)

Net cash used in operating activities

(31,747)

(18,026)

Investing activities:

Capital expenditures

(3,913)

(2,115)

Capitalized software

(26,918)

(11,144)

Proceeds from marketable securities

0

50,000

Acquisitions of business, net of cash acquired

0

(55,921)

Other, net

3,264

3,150

Net cash used in investing activities

(27,567)

(16,030)

Financing activities:

Net proceeds from the exercise of stock options

3,585

11,908

Repurchase of 2022 Notes

0

(130)

Proceeds from advances from financing companies

2,232

4,816

Payment against advances from financing companies

(3,921)

(4,098)

Proceeds from employee stock purchase plan

3,680

8,648

Cash received for withholding taxes on stock-based compensation, net

103

1,218

Other, net

(2,863)

(187)

Net cash provided by financing activities

2,816

22,175

Net decrease in cash and cash equivalents

(56,498)

(11,881)

Foreign exchange difference

(538)

(1,339)

Cash and cash equivalents at beginning of the period

893,480

733,324

Cash and cash equivalents at end of the period

$
836,444

$
720,104

Income taxes paid

$
261

$
52

Interest paid

$
7

$
3


	Quarter Ended March 31,
	2023		2022
Cash flows from operating activities:
Net loss	$	(69,228)	$	(6,674,523)
Adjustments to reconcile net loss to net cash flows from operating activities:
Goodwill impairment		0		6,600,000
Depreciation and amortization		69,783		58,933
Depreciation of rental equipment		681		770
Amortization of right-of-use assets		3,056		3,173
Provision for allowances		9,034		4,591
Stock-based compensation		46,038		60,436
Deferred income taxes		(355)		(2,319)
Accretion of interest		845		826
Other, net		(3,522)		0
Changes in operating assets and liabilities:
Accounts receivable		(14,046)		(27,842)
Prepaid expenses and other current assets		(6,165)		(18,993)
Inventory		10,000		2,023
Other assets		(9,939)		(6,047)
Accounts payable		(9,132)		492
Accrued expenses and other current liabilities		15,452		11,706
Accrued compensation		(32,265)		(48,819)
Deferred revenue		5,648		7,479
Operating lease liabilities		(2,858)		(3,626)
Other liabilities		129		(7)
Net cash provided by (used in) operating activities		13,156		(31,747)
Cash flows from investing activities:
Capital expenditures		(2,363)		(3,913)
Capitalized software		(43,261)		(26,918)
Other, net		0		3,264
Net cash used in investing activities		(45,624)		(27,567)
Cash flows from financing activities:
Net proceeds from the exercise of stock options		296		3,585
Proceeds from advances from financing companies		3,375		2,232
Payment against advances from financing companies		(3,548)		(3,921)
Proceeds from employee stock purchase plan		2,731		3,680
Cash received for withholding taxes on stock-based compensation, net		496		103
Other, net		3		(2,863)
Net cash provided by financing activities		3,353		2,816
Net decrease in cash and cash equivalents		(29,115)		(56,498)
Foreign exchange difference		(488)		(538)
Cash and cash equivalents at beginning of the period		918,182		893,480
Cash and cash equivalents at end of the period	$	888,579	$	836,444

Income taxes paid	$	346	$	261

Interest paid	$	194	$	7

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

TELADOC HEALTH, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Organization and Description of Business

Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care focusing on forging a new healthcare experience with better convenience, outcomes, and ~~value.~~value around the world. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience.

The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York.

On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of chronic healthcare for individuals around the world.

~~On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), a leading provider of enterprise telehealth solutions for hospitals and health systems.~~

Note 2. Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements for the ~~three months~~quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the condensed consolidated results of operations, financial position and cash flows of Teladoc Health for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, ~~2021~~2022 (the ~~“2021~~“2022 Form 10-K”), which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

These consolidated financial statements include the results of Teladoc Health, as well as 3two professional associations and 1210 professional corporations (collectively, the “THMG Association”). ~~All intercompany transactions and balances have been eliminated. Certain prior year amounts have been reclassified to conform to the current year presentation.~~

Teladoc Health Medical Group, P.A., formerly Teladoc Physicians, P.A. (“THMG”), is party to ~~several~~a Services ~~Agreements~~Agreement by and among it and the professional associations and professional corporations pursuant to which each professional association and professional corporation provides services to THMG. Each professional association and professional corporation is established pursuant to the requirements of its respective domestic jurisdiction governing the corporate practice of medicine.

The Company holds a variable interest in the THMG Association, which contracts with physicians and other health professionals in order to provide services to ~~the Company.~~Teladoc Health. The THMG Association is considered a variable interest entity (“VIE”) since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of the THMG Association and funds and absorbs all losses of the VIE and appropriately consolidates the THMG Association.

Total revenue and net ~~income (loss)~~loss for the VIE were $61.6 million and $0.0 million, and $60.1 million and ~~$2.3 million, and $54.2 million and $1.2~~($2.3) million, for the quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. The VIE’s total assets, all of which were current, were ~~$33.1~~$157.6 million and ~~$58.5~~$106.7 million at March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively. The VIE’s total liabilities, all of which were current, were ~~$71.5~~$206.2 million and ~~$94.7~~$143.8 million at March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively. The VIE’s total stockholders’ deficit was $48.6 million and $37.1 million at March 31, 2023 and December 31, 2022, respectively.

All intercompany transactions and balances have been eliminated.

Table of Contents

Certain prior year amounts have been reclassified to conform to the current year presentation.

~~respectively. The VIE’s total stockholders’ deficit was $38.4 million and $36.1 million at March 31, 2022 and December 31, 2021, respectively.~~

Business Combinations

The Company accounts for its business combinations using the acquisition method of accounting. The purchase price is attributed to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s condensed consolidated financial statements from the date of acquisition.

When the Company issues stock-based or cash awards to an acquired company’s stockholders, the Company evaluates whether the awards are consideration or compensation for post-acquisition services. The evaluation includes, among other things, whether the vesting of the awards is contingent on the continued employment of the acquired company’s stockholders beyond the acquisition date. If continued employment is required for vesting, the awards are treated as compensation for post-acquisition services and recognized as expense over the requisite service period.

Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain ~~assumed obligations.~~obligations assumed. Acquisition-related transaction costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.

Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in ~~reported results~~the Condensed Consolidated Statement of ~~operations;~~Operations; if material, the effects of changes in estimates are disclosed in the ~~notes~~Notes to ~~the condensed consolidated financial statements.~~Unaudited Condensed Consolidated Financial Statements.

Significant estimates and assumptions by management affect areas including the ~~carrying~~ value and useful life of long-lived assets (including intangible assets), the ~~carrying~~ value of goodwill, the capitalization and amortization of software development costs, deferred device and contract costs, ~~the allowance~~allowances for sales and for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance ~~guarantees,~~guarantees), the accounting for income taxes, ~~contingences,~~contingencies, litigation and related legal accruals, ~~and~~ the accounting for stock-based compensation awards, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the ~~2021~~2022 Form 10-K.

Recently Adopted Accounting Standards

In September 2022, the financial accounting standards board issued Accounting Standards Update (“ASU”) 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50) – Disclosure of Supplier Finance Program

Table of Contents

~~Recently Adopted Accounting Standards~~

~~In August 2020,~~Obligations,” to provide guidance on disclosure requirements for supplier finance programs and improve information transparency by requiring the financial accounting standards board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06—"Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifiesdisclosure of key terms of the ~~accounting for convertible instruments by eliminating the conversion option separation model for convertible debt~~program, amounts outstanding that ~~can be settled in cash and by eliminating the measurement model for beneficial conversion features. Convertible instruments that continue to be subject to separation models~~remain unpaid, a description of where those amounts are (1) those with conversion options that are required to be accounted for as bifurcated derivatives and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU also requires entities to use the if-converted method for all convertible instrumentspresented in the ~~diluted earnings per share calculation~~balance sheet, and ~~include the effect~~a rollforward of ~~share settlement~~any outstanding obligations. ASU 2022-04 is effective for ~~instruments that may be settled in cash or shares,~~annual reporting periods, including interim periods therein, beginning after December 15, 2022, except for ~~certain liability-classified share-based payment awards.~~

~~The Company adopted ASU 2020-06 as of January 1, 2022, under~~ the ~~modified retrospective transition method, and accordingly, its prior period financial statements were not restated. Upon~~amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. The adoption of ASU ~~2020-06, the conversion feature of~~2022-04 did not have any impact on the Company’s convertible senior notes is no longer reported as a component of equity. Instead, the previously-separated equity component is now combined with the liability component, thereby eliminating the amortization of the debt discount arising from the conversion option separation model. As such, the Company currently anticipates a reduction of approximately $58 million in non-cash interest to be recorded on its convertible senior notes for the year ended December 31, 2022, as compared to the year ended December 31, 2021. To reflect the adoption of ASU 2020-06, the Company recorded an increase to convertible senior notes of $306.3 million and decreases to additional paid-in capital, accumulated deficit and net deferred tax liabilities of $363.7 million, $72.7 million and $15.3 million, respectively, as of January 1, 2022.financial information.

Note 3. Revenue, Deferred Revenue, and Deferred Device and Contract Costs

The Company generates access fees from customers, ~~consisting~~which primarily consist of employers, health plans, hospitals and health systems, insurance and financial services companies (collectively “Clients”), as well as individual members who utilize the Company’s solutions, accessing its professional provider network, hosted virtual healthcare platform, and chronic care management platforms. Visit fee revenue is generated for general medical, expert medical service, and other specialty ~~visits. In addition,~~visits and is reported as a component of other revenue ~~is primarily~~in the condensed consolidated financial statements. Revenue associated with virtual healthcare device equipment sales included with ~~its~~the Company’s hosted virtual healthcare ~~platform.~~platform is also reported in other revenue. Access fees revenue accounted for ~~87%~~88% and ~~84%~~87% of the Company’s total revenue for the quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively.

~~Table of Contents~~

The following table presents the Company’s revenues disaggregated by revenue source and also by geography (in thousands):

Quarter Ended

March 31,


2022

2021

Access Fees Revenue

U.S.

$
421,146

$
327,553

International

70,191

54,553

Total

491,337

382,106

Visit Fee Revenue

U.S.

64,473

57,128

International

3,455

3,383

Total

67,928

60,511

Other

U.S.

5,581

10,671

International

504

387

Total

6,085

11,058

Total Revenues

$
565,350

$
453,675


	Quarter Ended
	March 31,
	2023		2022
Revenue by Type
Access fees	$	550,870	$	491,337
Other		78,374		74,013
Total Revenue	$	629,244	$	565,350

Revenue by Geography
U.S. Revenue	$	541,662	$	491,200
International Revenue		87,582		74,150
Total Revenue	$	629,244	$	565,350

During the fourth quarter of ~~2021,~~2022, the Company refined its definition of ~~international~~other revenue to capture revenues to reflect all international revenues based on location of the customer. Previously, Direct-to-Consumer (“D2C”) activities were primarily reflected based on the location of operations. In addition, certain activities related to the Company’s international operations are now reflected inassociated with visit ~~revenues versus access~~ fee, ~~revenues.~~virtual healthcare device equipment sales, and its hosted virtual healthcare platform. Prior period amounts have been recast to conform with the current presentation.

Deferred Revenue

Deferred revenue represents billed, but unrecognized revenue, and is comprised of fees received in advance of the delivery or completion of the services and amounts received in instances when revenue recognition criteria have not been met. Deferred revenue associated with upfront payments for a device is amortized ratably over the expected member enrollment period. Deferred revenue that will be recognized during the ~~succeeding~~next twelve-month period is recorded as current deferred revenue and the remaining portion is recorded as noncurrent deferred revenue.

For certain services, payment is required for future ~~months~~periods before the service is delivered to the member. The Company records deferred revenue when cash payments are received in advance of the Company’s performance obligation to provide services. Deferred revenue, current plus long-term, was $100.0 million at March 31, 2023 and $87.1 million at March 31, ~~2022 and $73.2 million at March 31, 2021.~~2022. The net increase of ~~$7.6~~$5.7 million and ~~$18.4~~$7.6 million in the deferred revenue balance for the ~~three months~~quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively, was primarily driven by ~~InTouch and Livongo as well as BetterHelp, the Company’s D2C mental health product, and~~increased cash payments received ~~or due~~ in advance of satisfying ~~the Company’s~~ performance obligations primarily related to the services of the BetterHelp segment and, to a lesser extent, the Teladoc Health Integrated Care segment, offset by revenue recognized that ~~were~~was included in the deferred revenue balance at the beginning of the period. The Company anticipates that it will satisfy most of its performance obligation associated with the deferred revenue within the prospective fiscal year. Revenue recognized during the ~~quarters~~quarter ended March 31, ~~2022~~2023 and ~~2021~~2022 that was included in deferred revenue at the beginning of the periods was ~~$51.6~~$61.5 million and ~~$32.7~~$51.6 million, respectively.

~~The Company expects to recognize $73.0 million and $5.0 million of revenue in~~ ~~2022~~ ~~and~~ ~~2023, respectively, related to future performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2022.~~

Table of Contents

The Company expects to recognize $87.8 million of revenue throughout the remainder of 2023 and $10.6 million of revenue in the year ending December 31, 2024 related to future performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2023.

Deferred Device and Contract Costs

Deferred device and contract costs are classified as a component of ~~Prepaid~~prepaid expenses and other current assets or ~~Other~~other assets, depending on term, and consisted of the following ~~as of March 31, 2022~~ (in thousands):


	As of March 31,		As of December 31,		As of March 31,		As of December 31,
	2022		2021		2023		2022
Deferred device and contract costs, current	$	27,335	$	22,304	$	26,576	$	29,956
Deferred device and contract costs, noncurrent		7,636		6,249		17,033		8,404
Total deferred device and contract costs	$	34,971	$	28,553	$	43,609	$	38,360

Deferred ~~costs~~device and ~~other activity~~contract costs were as follows (in thousands):

Deferred Device and Contract Costs
Beginning balance as of December 31, 2021

$
28,553
Additions

13,986
Cost of revenue recognized

(7,568)
Ending balance as of March 31, 2022

$
34,971

~~Table of Contents~~

~~Note 4. Inventories~~

~~Inventories consisted of the following (in thousands):~~

As of March 31,

As of December 31,

2022

2021

Raw materials and purchased parts

$
25,006

$
26,164

Work in process

379

313

Finished goods

45,269

46,602

Total inventories

$
70,654

$
73,079

~~Note 5. Prepaid Expenses and Other Current Assets~~

~~Prepaid expenses and other current assets consisted of the following (in thousands):~~

As of March 31,

As of December 31,

2022

2021
Prepaid expenses

$
51,397

$
38,179
Deferred device and contract costs, current

27,335

22,304
Other receivables

22,817

21,170
Other current asset

5,326

5,734
Total prepaid expenses and other current assets

$
106,875

$
87,387


	Deferred Device and Contract Costs
Beginning balance as of December 31, 2022	$	38,360
Additions		16,572
Cost of revenue recognized		(11,323)
Ending balance as of March 31, 2023	$	43,609

Note ~~6. Intangible Assets, Net~~4. Fair Value Measurements

~~Intangible assets, net consist~~

The carrying value of the Company’s cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.

A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:

Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active

markets.

Level 2—Include other inputs that are directly or indirectly observable in the marketplace.

Level 3—Unobservable inputs that are supported by little or no market activity.

The Company measures its cash equivalents at fair value on a recurring basis. The Company classifies its cash equivalents within Level 1 because they are valued using observable inputs that reflect quoted prices for identical assets in active markets and quoted prices directly in active markets.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis using the above input categories (in thousands):

Weighted

Average




Remaining

Useful



Accumulated

Net Carrying

Useful Life

Life

Gross Value

Amortization

Value

(Years)

March 31, 2022

Client relationships

2 to 20 years

$
1,463,335

$
(222,285)

$
1,241,050

14.3

Trademarks

2 to 15 years

325,958

(58,823)

267,135

7.4

Software

3 to 5 years

155,456

(45,101)

110,355

2.8

Technology

5 to 7 years

343,310

(77,953)

265,357

5.3

Intangible assets, net

$
2,288,059

$
(404,162)

$
1,883,897

11.4

December 31, 2021

Client relationships

2 to 20 years

$
1,465,926

$
(199,866)

$
1,266,060

14.5

Trademarks

3 to 15 years

326,392

(45,555)

280,837

9.5

Software

3 to 5 years

126,188

(40,767)

85,421

2.7

Technology

5 to 7 years

343,262

(65,302)

277,960

5.6

Intangible assets, net

$
2,261,768

$
(351,490)

$
1,910,278

12.0


	March 31, 2023
	Level 1		Level 2		Total
Cash and cash equivalents	$	888,579	$	0	$	888,579

Amortization expense for intangible assets net of foreign currency remeasurement for intangible assets was $56.6 million and $46.6 million for the quarters ended March 31, 2022 and 2021, respectively.

In January 2022, the Company embarked upon a two-year migration strategy that integrates and moves selected consumer brands under Teladoc Health – which will serve as the primary business-to-business-to-consumer brand that meets all consumer healthcare needs. The evolution of brand names results in the weighted average life of our trademarks decreasing from 9.5 years to 7.4 years as of March 31, 2022, and an acceleration of amortization expense being expensed over 2022 and 2023. This change resulted in additional amortization expense of $5.8 million (or $0.04 per basic and diluted share) in the first quarter of 2022.

~~Refer to Note 7 to the condensed consolidated financial statements for the results of impairment testing of the Company’s intangible assets including goodwill.~~


	December 31, 2022
	Level 1		Level 2		Total
Cash and cash equivalents	$	918,182	$	0	$	918,182

119

Table of Contents

~~Note 7. Goodwill~~

~~Goodwill consisted~~There were no transfers between fair value measurement levels during any of the ~~following (in thousands):~~

As of March 31,

As of December 31,

2022

2021

Beginning balance as of December 31, 2021 and 2020, respectively

$
14,504,174

$
14,581,255

Impairment

(6,600,000)

0

Additions associated with acquisitions

0

64,269

Purchase consideration adjustments net of deferred tax impacts

0

(122,306)

Currency translation adjustment

(4,379)

(19,044)

Ending balance as of March 31, 2022 and December 31, 2021

$
7,899,795

$
14,504,174

periods presented.

As a result of sustained decreases in the Company’s publicly quoted share price and market capitalization continuing into 2022, the Company conducted additional testing of its goodwill, definite-lived intangibles, and other long-lived assets as of March 31, 2022. As a result of this review, the Company did not identify an impairment to its definite-lived intangible assets or other long-lived assets, but the Company recorded a $6.6 billion non-deductible, non-cash goodwill impairment charge (or $41.11 per basic and diluted share) for the quarter ended March 31, 2022.

Consistent with prior goodwill impairment testing, the Company’s March 31, 2022, testing reflected a 75%/25% allocation between the income and market approaches. The Company believes the 75% weighting to the income approach continues to be appropriate as it more directly reflects its future growth and profitability expectations. For the Company’s March 31, 2022 impairment testing, as compared to its December 1, 2021 testing, the Company reduced its estimated future cash flows used in the impairment assessment, including revenues, margin, and capital expenditures to reflect its best estimates at this time. The Company also updated certain significant inputs into the valuation models including the discount rate which increased reflecting, in part, higher interest rates and market volatility, and the Company reduced its revenue market multiples, reflecting declining valuations across the Company’s selected peer group. The Company’s updates to its discount rate, market multiples, and estimated future cash flows each had a significant impact to the estimated fair value of the reporting unit.

~~The following table reflects changes in the most significant inputs to the Company’s impairment analysis on each testing date since its last annual test.~~

Testing dates
Discount Rate
Peer Group Revenue Multiples
(current year/subsequent year)
% Excess of Reporting Unit Fair Value over Carrying Value
December 1, 2021
10.5%
7.0x/5.5x
15.0%
March 31, 2022
12.0%
3.0x/2.5x
0% post impairment

Note 5. Inventories

Inventories consisted of the following (in thousands):


	As of March 31,		As of December 31,
	2023		2022
Raw materials and purchased parts	$	26,403	$	30,126
Work in process		934		433
Finished goods		26,338		31,977
Inventory reserve		(7,874)		(6,194)
Total inventories	$	45,801	$	56,342

Note ~~8. Accrued~~6. Prepaid Expenses and Other Current ~~Liabilities~~Assets

~~Accrued~~

Prepaid expenses and other current ~~liabilities~~assets consisted of the following (in thousands):

As of March 31,

As of December 31,

2022

2021

Professional fees

$
5,485

$
5,373

Consulting fees/provider fees

18,029

19,292

Client performance guarantees

10,034

7,653

Interest payable

5,809

1,480

Income tax payable

5,131

3,098

Insurance

5,779

3,884

Marketing

6,104

3,471

Operating lease liabilities - current

13,052

12,687

Franchise and sales taxes

11,429

9,965

Device replacement cost

5,913

6,263

Other

29,924

29,767

Total

$
116,689

$
102,933


	As of March 31,		As of December 31,
	2023		2022
Prepaid expenses	$	77,526	$	63,159
Deferred device and contract costs, current		26,576		29,956
Other receivables		25,099		25,091
Other current assets		7,145		12,104
Total prepaid expenses and other current assets	$	136,346	$	130,310

Note 7. Goodwill

Goodwill consisted of the following (in thousands):



		Teladoc Health Integrated Care		BetterHelp		Total
Balance as of December 31, 2022 and March 31, 2023	$	0	$	1,073,190	$	1,073,190

Goodwill is net of accumulated impairment losses of $13.4 billion, of which $12.3 billion was recognized prior to the Company reorganizing its reporting structure to include two reportable segments on October 1, 2022 and $1.1 billion was recognized on the goodwill assigned to the Teladoc Health Integrated Care segment.

1210

Table of Contents

Note ~~9. Fair Value Measurements~~8. Intangible Assets, Net and Certain Cloud Computing Costs

~~The carrying value~~Intangible assets, net consisted of the ~~Company’s cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.~~

The Company measures its financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires it to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:

~~Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active~~

~~markets.~~

~~Level 2—Include other inputs that are directly or indirectly observable in the marketplace.~~

~~Level 3—Unobservable inputs that are supported by little or no market activity.~~

The Company’s short-term investments held as of March 31, 2022 and 2021 consisted primarily of certificates of deposit held at financial institutions. The amortized cost of these investments, which are classified as Level 2, approximated their fair value.

~~The~~ following ~~tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis using the above input categories~~ (in thousands):

March 31, 2022


Level 1

Level 2

Total
Cash and cash equivalents

$
836,444

$
0

$
836,444
Short-term investments

$
0

$
2,544

$
2,544


	December 31, 2021													Weighted
	Level 1		Level 2		Total									Average
Cash and cash equivalents	$	893,480	$	0	$	893,480
Short-term investments	$	0	$	2,537	$	2,537
														Remaining
							Useful			Accumulated		Net Carrying		Useful Life
							Life	Gross Value		Amortization		Value		(Years)
March 31, 2023
Client relationships							2 to 20 years	$	1,459,719	$	(316,839)	$	1,142,880	13.3
Trademarks							2 to 15 years		325,368		(111,724)		213,644	6.9
Software							3 to 5 years		339,643		(94,838)		244,805	2.7
Technology							4 to 7 years		343,070		(128,451)		214,619	4.4
Intangible assets, net								$	2,467,800	$	(651,852)	$	1,815,948	10.1
December 31, 2022
Client relationships							2 to 20 years	$	1,458,384	$	(291,993)	$	1,166,391	13.5
Trademarks							2 to 15 years		325,171		(98,303)		226,868	7.0
Software							3 to 5 years		294,629		(78,373)		216,256	2.7
Technology							4 to 7 years		343,067		(115,817)		227,250	4.7
Intangible assets, net								$	2,421,251	$	(584,486)	$	1,836,765	10.4

~~There were no transfers between fair value measurement levels during~~Amortization expense for intangible assets was $66.9 million and $56.6 million for the quarters ended March 31, 2023 and 2022, respectively. Included in the total amortization expense was amortization for capitalized software development cost of $16.6 million and $6.7 million for the quarters ended March 31, 2023 and 2022, respectively.

Net cloud computing costs are recorded in other assets within the balance sheets. As of March 31, 2023 and December 31, ~~2021.~~2022, those costs were $32.5 million and $25.4 million, respectively. The associated expense for cloud computing costs is amortized in general and administration expense and was $0.8 million and $0.3 million for the quarters ended March 31 2023 and 2022, respectively.

~~Note 10. Leases~~

The Company has operating leases for facilities, hosting co-location facilities and certain equipment under non-cancelable leases in the U.S. and various international locations. The leases have remaining lease terms of 1 ~~to 11 years, with options to extend the lease term from~~ 1 to 6 years. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the arrangement covering the right to use property, plant or equipment for a stated period of time. For new and amended leases beginning in 2020 and after, the Company separately allocates the lease (e.g., fixed lease payments for right-to-use land, building, etc.) and non-lease components (e.g., common area maintenance) for its leases.

~~Table of Contents~~

~~Operating Leases~~Note 9. Accrued Expenses and Other Current Liabilities

~~The Company leases office space under non-cancelable operating leases in~~Accrued expenses and other current liabilities consisted of the ~~U.S. and various international locations. As of March 31, 2022, the future minimum lease payments under non-cancelable operating leases were as follows~~following (in thousands):


	As of March 31,		As of December 31,
	2023		2022
Professional fees	$	14,158	$	10,152
Consulting fees/provider fees		22,345		16,407
Client performance guarantees		6,909		4,145
Interest payable		5,811		1,480
Income tax payable		4,694		3,817
Insurance		5,125		5,981
Lease abandonment obligation - current		3,136		0
Marketing		40,427		35,055
Operating lease liabilities – current		12,958		13,592
Franchise and sales taxes		13,272		10,183
Accrued rebates		17,831		14,542
Staff augmentation		4,479		3,391
Other		33,497		49,948
Total	$	184,642	$	168,693

Table of Contents

As of March 31,
Operating Leases:

2022
2022

$
15,023
2023

14,261
2024

9,634
2025

7,197
2026

5,822
2027 and thereafter

12,638
Total future minimum payments

$
64,575

The Company rents certain information systems to selected qualified customers under arrangements that qualify as either sales-type lease or operating lease arrangements. Leases have terms that generally range from

2 ~~to 5 years.~~

Note ~~11.~~10. Convertible Senior Notes

Outstanding Convertible Senior Notes

As of March 31, ~~2022,~~2023, the Company had three series of convertible senior notes outstanding. The issuances of such notes originally consisted of (i) $1.0 billion aggregate principal amount of 1.25% convertible senior notes due 2027 (the “2027 Notes”), issued on May 19, 2020 for net proceeds to the Company of $975.9 million after deducting offering costs of approximately $24.1 million, (ii) $287.5 million aggregate principal amount of 1.375% convertible senior notes due 2025 (the “2025 Notes”), issued on May 8, 2018 for net proceeds to the Company of $279.1 million after deducting offering costs of approximately $8.4 million, and (iii) $550.0 million aggregate principal amount of 0.875% convertible senior notes due 2025 that were issued by Livongo on June 4, 2020 for which the Company ~~has~~had agreed to guarantee Livongo’s obligations (the “Livongo Notes;” and together with the 2027 Notes and the 2025 Notes, ~~and the 2022 Notes (as defined below),~~ the “Notes”). On ~~June 27, 2017,~~January 1, 2023, the Company ~~issued, at par value, $275.0 million aggregate principal amount~~agreed to assume all of ~~3% convertible senior notes due 2022 (the “2022 Notes”), which were redeemed during~~Livongo’s rights and obligations under the ~~quarter ended March 31, 2021 as described below.~~Livongo Notes and the applicable indenture, and Livongo was released from such obligations.

The following table presents certain terms of the Notes that were outstanding as of March 31, ~~2022:~~2023:

2027 Notes

2025 Notes

Livongo Notes

Interest Rate Per Year

1.25
%

1.375
%

0.875
%
Fair Value as of March 31, 2022 (in millions) (1)
$
843.5

$
1.0

$
553.3

Fair Value as of December 31, 2021 (in millions) (1)
$
940.0

$
1.3

$
605.0

Maturity Date

June 1, 2027

May 15, 2025

June 1, 2025

Optional Redemption Date

June 5, 2024

May 22, 2022

June 5, 2023

Conversion Date

December 1, 2026

November 15, 2024

March 1, 2025

Share Conversion Rate Per $1,000 Principal Amount as of March 31, 2022

4.1258

18.6621

13.94

Remaining Contractual Life as of March 31, 2022

5.2 years

3.1 years

3.2 years


	2027 Notes			2025 Notes			Livongo Notes
Principal Amount Outstanding as of March 31, 2023 (in millions)	$	1,000.0		$	0.7		$	550.0
Interest Rate Per Year		1.25	%		1.375	%		0.875	%
Fair Value as of March 31, 2023 (in millions) (1)	$	771.3		$	0.4		$	484.3
Fair Value as of December 31, 2022 (in millions) (1)	$	768.2		$	0.3		$	480.6
Maturity Date		June 1, 2027			May 15, 2025			June 1, 2025
Optional Redemption Date		June 5, 2024			May 22, 2022			June 5, 2023
Conversion Date		December 1, 2026			November 15, 2024			March 1, 2025
Conversion Rate Per $1,000 Principal Amount as of March 31, 2023		4.1258			18.6621			13.94
Remaining Contractual Life as of March 31, 2023		4.2 years			2.1 years			2.2 years

(1)

The Notes are classified as Level 12 within the fair value hierarchy, as defined in Note 9.4. “Fair Value Measurements.”

All of the Notes are unsecured obligations of the Company and rank senior in right of payment to the Company’s indebtedness that is expressly subordinated in right of payment to such Notes; equal in right of payment to the Company’s liabilities that are not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities incurred by the Company’s subsidiaries.

~~Table of Contents~~

Holders may convert all or any portion of their Notes in integral multiples of $1,000 principal amount, at their option, at any time prior to the close of business on the business day immediately preceding the applicable conversion date only under the following circumstances:

●

during any quarter (and only during such quarter), if the last reported sale price of the shares of Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding quarter is greater than or equal to 130% of the conversion price for the applicable Notes on each applicable trading day;

●

during the 5five business day period after any 10ten consecutive trading day period (or 5five consecutive trading day period in the case of the Livongo Notes) in which the trading price was less than 98% of the product of the last reported sale price of Company’s common stock and the conversion rate for the applicable Notes on each such trading day;

●

upon the occurrence of specified corporate events described under the applicable indenture; or

Table of Contents

●

if the Company calls the applicable Notes for redemption, at any time until the close of business on the second business day immediately preceding the redemption date.

On or after the applicable conversion date, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of such Notes, regardless of the foregoing circumstances.

The 2027 Notes and the 2025 Notes are convertible into shares of the Company’s common stock at the applicable conversion rate shown in the table above. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. If the Company elects to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, ~~or units of reference property,~~ the amount of cash and shares of the Company’s common stock due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 25 consecutive trading day observation period.

The Livongo Notes are convertible at the applicable conversion rate shown in the table above into “units of reference property,” each of which is comprised of ~~0.5920~~0.592 of a share of the Company’s common stock and $4.24 in cash, without interest. Upon conversion, the Company will pay or deliver, as the case may be, cash, units of reference property, or a combination thereof, at the Company’s election. If the Company elects to satisfy the conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and units of reference property, the amount of cash and units of reference property, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 consecutive trading day observation period.

For each Note series, the Company may redeem for cash all or part of the Notes, at its option, on or after the applicable optional redemption date shown in the table above (and prior to the ~~41st~~41^st scheduled trading day immediately preceding the maturity date in the case of the Livongo Notes) if the last reported sale price of its common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the trading day immediately preceding the date on which the Company provides notice of the redemption. The redemption price will be the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any. In addition, calling any 2027 Note or 2025 Note for redemption on or after the applicable optional redemption date will constitute a make-whole fundamental change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note, if it is converted in connection with the redemption, will be increased in certain circumstances as described in the applicable indenture. If ~~Livongo~~the Company undergoes a fundamental change (as defined in the applicable indenture) at any time prior to the maturity date of the Livongo Notes, holders will have the right, at their option, to require ~~Livongo~~the Company to repurchase for cash all or any portion of their Livongo Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Livongo Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

~~Following the adoption of ASU 2020-06 on January 1, 2022 as described in Note 2, the~~

The Company accounts for each Note series at amortized cost within the liability section of its condensed consolidated balance sheets. The Company has reserved an aggregate of 8.7 million shares of common stock for the Notes.

1513

Table of Contents

The net carrying values of the Notes consisted of the following (in thousands):

As of March 31,

As of December 31,
2027 Notes

2022

2021
Principal

$
1,000,000

$
1,000,000
Less: Debt discount, net (1)

(17,940)

(250,846)
Net carrying amount

$
982,060

$
749,154

2025 Notes

Principal

$
730

$
730
Less: Debt discount, net (1)

(10)

(166)
Net carrying amount

$
720

$
564

Livongo Notes

Principal

$
550,000

$
550,000
Less: Debt discount, net (1)

0

(74,047)
Net carrying amount

$
550,000

$
475,953


	As of March 31,		As of December 31,
2027 Notes	2023		2022
Principal	$	1,000,000	$	1,000,000
Less: Debt discount, net (1)		(14,584)		(15,430)
Net carrying amount		985,416		984,570

2025 Notes
Principal		725		725
Less: Debt discount, net (1)		(7)		(7)
Net carrying amount		718		718

Livongo Notes
Principal		550,000		550,000
Less: Debt discount, net (1)		0		0
Net carrying amount		550,000		550,000

Total net carrying amount	$	1,536,134	$	1,535,288

(1)

Included in the accompanying condensed consolidated balance sheet within convertible senior notes and amortized to interest expense over the expected life of the Notes using the effective interest rate method.

The Company estimates the fair value of its Notes utilizing market quotations for debt that have quoted prices in active markets. Since the Notes do not trade on a daily basis in an active market, the fair value estimates are based on market observable inputs based on borrowing rates currently available for debt with similar terms and average maturities.

The following table sets forth total interest expense recognized related to the Notes (in thousands):

Quarter Ended

March 31,

2027 Notes:

2022

2021

Contractual interest expense
$
3,125

$
3,125

Amortization of debt discount

831

9,059

Total
$
3,956

$
12,184

Effective interest rate

0.8
%

3.4
%

Quarter Ended

March 31,
2025 Notes:

2022

2021

Contractual interest expense
$
3

$
814

Amortization of debt discount

1

2,719

Total
$
4

$
3,533

Effective interest rate

0.9
%

3.9
%

Quarter Ended

March 31,

Livongo Notes:

2022

2021

Contractual interest expense
$
1,203

$
1,203

Amortization of debt discount

0

4,734

Total
$
1,203

$
5,937

Effective interest rate

0
%

5.2
%

Quarter Ended

March 31,
2022 Notes:

2022

2021

Contractual interest expense
$
0

$
104

Amortization of debt discount

0

316

Total
$
0

$
420

Effective interest rate

0
%

9.6
%


	Quarters Ended
	March 31,
2027 Notes		2023			2022
Contractual interest expense	$	3,125		$	3,125
Amortization of debt discount		844			831
Total	$	3,969		$	3,956
Effective interest rate		1.6	%		0.8	%

	Quarters Ended
	March 31,
2025 Notes		2023			2022
Contractual interest expense	$	2		$	3
Amortization of debt discount		1			1
Total	$	3		$	4
Effective interest rate		1.6	%		0.9	%

	Quarters Ended
	March 31,
Livongo Notes		2023			2022
Contractual interest expense	$	1,203		$	1,203
Amortization of debt discount		0			0
Total	$	1,203		$	1,203
Effective interest rate		1.3	%		0	%

1614

Table of Contents

~~Conversions of Convertible Senior Notes Due 2025~~

Certain holders of the 2025 Notes converted their 2025 Notes in exchange for 1.1 million shares of the Company’s common stock during the quarter ended March 31, 2021. As a result, the Company recorded a charge associated with the loss on extinguishment of debt of $8.1 million during the quarter ended March 31, 2021.

~~Redemption of Convertible Senior Notes Due 2022~~

In March 2021, the Company completed a redemption of all of the then outstanding 2022 Notes in exchange for approximately $0.1 million in cash (including accrued and unpaid interest). Prior to that redemption, certain holders of the 2022 Notes converted their 2022 Notes in exchange for 1.1 million shares of the Company’s common stock during the quarter ended March 31, 2021. As a result of the redemption and conversions, the Company recorded a charge associated with the loss on extinguishment of debt of $3.4 million during the quarter ended March 31, 2021.

Note ~~12.~~11. Advances from Financing Companies

The Company utilizes a third-party financing company to provide certain Clients with a rental option. The principal portion of these up-front payments are reported as advances from financing companies in the accompanying condensed consolidated balance ~~sheet.~~sheets. Interest rates applicable to the outstanding advances as of March 31, ~~2022~~2023 ranged from 3.35% to ~~8.25%~~10.98%.

Client lease payments to third party financing companies will reduce the advances from financing companies as of March 31, ~~2022~~2023 by year as follows (in thousands):


	As of March 31,		As of March 31,
	2022		2023
2022	$	10,105
2023		8,024
Remainder of 2023			$	8,908
2024		2,678		7,382
2025		109		2,903
2026				91
Total	$	20,916	$	19,284

~~Note 13. Legal Matters~~

From time to time, Teladoc Health is involved in various litigation matters arising in the normal course of business, including the matters described below. The Company consults with legal counsel on those issues related to litigation and seeks input from other experts and advisors with respect to such matters. Estimating the probable losses or a range of probable losses resulting from litigation, government actions and other legal proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, may involve discretionary amounts, present novel legal theories, are in the early stages of the proceedings, or are subject to appeal. Whether any losses, damages or remedies ultimately resulting from such matters could reasonably have a material effect on the Company’s business, financial condition, results of operations, or cash flows will depend on a number of variables, including, for example, the timing and amount of such losses or damages (if any) and the structure and type of any such remedies. As of the date of these financial statements, Teladoc Health’s management does not expect any litigation matter to have a material adverse impact on its business, financial condition, results of operations or cash flows.

On May 14, 2018, a purported class action complaint (Thomas v. Best Doctors, Inc.) was filed in the United States District Court for the District of Massachusetts against the Company’s wholly owned subsidiary, Best Doctors, Inc. The complaint alleges that on or about May 16, 2017, Best Doctors violated the U.S. Telephone Consumer Protection Act (the “TCPA”) by sending unsolicited facsimiles to plaintiff and certain other recipients without the recipients’ prior express invitation or permission. The lawsuit seeks statutory damages for each violation, subject to trebling under the TCPA, and injunctive relief. The Company will vigorously defend the lawsuit and any potential loss is currently deemed to be immaterial.

~~Table of Contents~~

certain of the Company’s current and former officers and directors. The complaint was brought on behalf of a purported class consisting of all persons who acquired shares of Teladoc Health common stock issued in the Livongo merger. The complaint asserted violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 based on allegedly false or misleading statements and omissions with respect to the registration statement and prospectus filed in connection with the Livongo merger. The complaint sought certification as a class action, unspecified compensatory damages plus interest and attorneys’ fees, rescission or a rescissory measure of damages and equitable or other relief. On January 18, 2022, the case was voluntarily dismissed without prejudice in the Circuit Court of Cook County, Illinois and on January 26, 2022, was refiled in the Supreme Court of the State of New York. The refiled case includes substantially the same allegations. The Company believes that these claims are without merit, and the Company and its named current and former officers and directors intend to defend the Company vigorously.

Note 12. Leases

The Company has operating leases for facilities, hosting co-location facilities, and certain equipment under non-cancelable leases in the U.S. and various international locations. The leases have remaining lease terms of less than one to 10 years, with options to extend the lease term from one to five years. At the inception of an arrangement, the Company determines whether the arrangement is, or contains, a lease based on the terms covering the right to use property, plant or equipment for a stated period of time. For new and amended leases beginning in 2020 and after, the Company separately allocates the lease (e.g., fixed lease payments for right-to-use land, building, etc.) and non-lease components (e.g., common area maintenance) for its leases.

The Company leases office space under non-cancelable operating leases in the U.S. and various international locations. The future minimum lease payments under non-cancelable operating leases were as follows (in thousands):


	As of March 31,
Operating Leases:	2023
2023	$	11,783
2024		11,176
2025		8,615
2026		7,547
2027		5,436
2028 and thereafter		13,375
Total future minimum payments		57,932
Less: imputed interest		(9,047)
Present value of lease liabilities	$	48,885

Accrued expenses and other current liabilities	$	12,958
Operating lease liabilities, net of current portion	$	35,927

Table of Contents

The Company recorded certain restructuring costs related to lease impairments and the related charges due to the abandonment and/or exit of excess leased office space. However, the lease liabilities related to these spaces remain an outstanding obligation of the Company as of March 31, 2023. See Note. 13, “Restructuring,” for further information.

Note 13. Restructuring

The Company is continuing the previously reported actions to restructure its operations to reduce operating costs. In connection with the restructuring, the Company expects to incur approximately $17 million in pre-tax charges in the year ending December 31, 2023, consisting of $9 million substantially related to employee transition, severance payments, employee benefits, and related costs and approximately $8 million of costs associated with office space reductions. The Company accounts for restructuring costs in accordance with ASC Subtopic 420-10, "Exit or Disposal Cost Obligations" and ASC Section 360-10-35, “Property, Plant and Equipment-Subsequent Measurement.” The costs are recorded to the "Restructuring costs" line item within the Company's Consolidated Statements of Operations and Other Comprehensive Loss as they are recognized.

During the quarter ended March 31, 2023, the Company recorded $8.1 million of restructuring costs, of which $7.2 million was related to employee transition, severance payments, employee benefits, and related costs and $0.9 million was related to costs associated with office space reductions. The portion of these amounts to be settled by cash disbursements was accounted for as a restructuring liability under the line item "Accrued expenses and other current liabilities" in the Company's Condensed Consolidated Balance Sheets.

The Company expects to incur the remaining approximately $9 million in pre-tax charges in the second quarter of 2023. Such charges are expected to principally relate to costs associated with office space reductions.

The table below summarizes the accrual and charges incurred with respect to the Company's restructuring that are included in the line items "Accrued expenses and other current liabilities" in the Company's Consolidated Balance Sheet as of March 31, 2023 (in thousands):


	Restructuring Plan
	Severance		Lease Termination		Total
Accrued Balance, December 31, 2022	$	796	$	3,247	$	4,043
Additions		7,170		470		7,640
Cash payments		(5,932)		(581)		(6,513)
Accrued Balance, March 31, 2023	$	2,034	$	3,136	$	5,170

Note 14. Common Stock and Stockholders’ Equity

~~Capitalization~~

~~Effective October 30, 2020, the authorized number of shares of the Company’s common stock was increased from 150,000,000 to 300,000,000 shares.~~

~~Warrants~~

~~The Company had 0 warrants outstanding as of March 31, 2022 or December 31, 2021.~~

Stock Plans

The Company’s 2015 Incentive Award Plan, 2017 Employment Inducement Incentive Award Plan and Livongo Acquisition Incentive Award Plan (collectively, the “Plans”) provide for the issuance of incentive and non-statutory options and other equity-based awards to its employees and non-employee service providers. The Company had 6,278,157 shares available for grant at March 31, 2023.

All stock-based awards to employees are measured based on the grant-date fair value, or replacement grant date fair value in relation to the Livongo transaction, and are generally recognized on a straight line basis in the Company’s condensed consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period for each stock option and a three-year vesting period for each restricted stock unit (“RSU”)). The Company recognizes the forfeiture of stock-based awards as they occur.

Stock Options

Options issued under the Plans are exercisable for periods not to exceed ~~ten~~10 years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. The Company had 10,218,931 shares available for grant at March 31, 2022.

~~Activity under the Plans was as follows (in thousands, except share and per share amounts and years):~~

Weighted-


Weighted-

Average

Number of

Average

Remaining

Aggregate

Shares

Exercise

Contractual

Intrinsic

Outstanding

Price

Life in Years

Value

Balance at December 31, 2021

3,426,978

$
22.88

5.32

$
242,569

Stock option grants

45,434

$
79.40

N/A

Stock options exercised

(267,586)

$
13.40

N/A

$
(15,090)

Stock options forfeited

(15,767)

$
19.63

N/A

Balance at March 31, 2022

3,189,059

$
24.50

5.16

$
160,501

Vested or expected to vest at March 31, 2022

3,189,059

$
24.50

8.35

$
2,352

Exercisable at March 31, 2022

3,011,138

$
20.36

4.97

$
158,148

~~The total grant-date fair value of stock options granted during the quarters ended March 31, 2022 and 2021 were $1.6 million and $0.4 million, respectively.~~

1816

Table of Contents

under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award.

Stock option activity under the Plans was as follows (in thousands, except share and per share amounts and years):


				Weighted-
		Weighted-		Average
	Number of	Average		Remaining	Aggregate
	Shares	Exercise		Contractual	Intrinsic
	Outstanding	Price		Life in Years	Value
Balance at December 31, 2022	4,243,934	$	27.79	6.10	$	19,541
Stock option grants	20,431	$	23.65	N/A
Stock options exercised	(28,127)	$	10.51	N/A	$	(475)
Stock options forfeited	(40,725)	$	47.20	N/A
Balance at March 31, 2023	4,195,513	$	27.69	5.79	$	23,800
Vested or expected to vest at March 31, 2023	4,195,513	$	27.69	5.79	$	23,800
Exercisable at March 31, 2023	2,716,055	$	23.11	3.94	$	23,711

The total grant-date fair value of stock options granted during the quarters ended March 31, 2023 and 2022 were $0.2 million and $1.6 million, respectively.

The Company estimates the fair value of stock options granted using the ~~Black Scholes~~Black-Scholes option pricing model.

The assumptions used ~~in the Black-Scholes option-pricing model~~ are determined as follows:

Volatility. The expected volatility was derived from the historical stock volatilities of the Company’s stock ~~volatility~~ over a period equivalent to the expected term of the stock option grants.

Expected Term. The expected term represents the period that the stock-based awards are expected to be outstanding. When establishing the expected term assumption, the Company utilizes historical data.

Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with terms similar to the expected term on the options.

Dividend Yield. The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future and, therefore, it used an expected dividend yield of 0.zero.

~~Forfeiture rate.~~ ~~The Company recognizes forfeitures as they occur.~~

The fair value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions and fair value per share:


	Quarter Ended March 31,				Quarter Ended March 31,
	2022		2021		2023		2022
Volatility		56.69% - 57.86%		57.02% - 57.49%		65.58%		56.69% - 57.86%
Expected term (in years)		4.1		4.1		4.3		4.1
Risk-free interest rate		1.13% - 1.52%		0.31% - 0.51%		4.07%		1.13% - 1.52%
Dividend yield		0		0		0		0
Weighted-average fair value of underlying stock options	$	$35.94	$	$107.06	$	12.85	$	35.94

For the quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, the Company recorded compensation expense related to stock options granted of $2.2 million and $10.7 million, ~~and $28.2 million,~~ respectively.

As of March 31, ~~2022,~~2023, the Company had ~~$10.9~~$21.0 million in unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted-average period of approximately 2.4 years.

~~1.9 years.~~

Table of Contents

Restricted Stock Units

The fair value of RSUs is determined on the date of grant. The Company records compensation expense in the ~~condensed~~ consolidated statement of operations on a straight-line basis over the vesting period for RSUs. The vesting period for employees and members of the Board of Directors ranges from one to ~~four~~three years.

~~Activity~~RSU activity under ~~RSUs~~the Plans was as follows:


		Weighted-Average			Weighted-Average
		Grant Date			Grant Date
	RSUs	Fair Value Per RSU		RSUs	Fair Value Per RSU
Balance at December 31, 2021	2,133,501	$	168.43
Balance at December 31, 2022				6,481,669	$	63.63
Granted	2,433,620	$	74.74	6,301,052	$	26.83
Vested and issued	(499,486)	$	146.13	(942,132)	$	100.72
Forfeited	(153,581)	$	153.09	(425,795)	$	71.47
Balance at March 31, 2022	3,914,054	$	113.99
Vested and unissued at March 31, 2022	16,507	$	71.96
Non-vested at March 31, 2022	3,897,547	$	113.99
Balance at March 31, 2023				11,414,794	$	39.96
Vested and unissued at March 31, 2023				23,878	$	92.15
Non-vested at March 31, 2023				11,390,916	$	39.85

The total grant-date fair value of RSUs granted during the quarters ended March 31, 2023 and 2022 was $169.1 million and ~~2021 was~~ $181.9 million, ~~and $88.0 million,~~ respectively.

For the quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, the Company recorded stock-based compensation expense related to RSUs of $43.4 million and $44.5 million, ~~and $50.9 million,~~ respectively.

As of March 31, ~~2022,~~2023, the Company had ~~$407.8~~$405.9 million in unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted-average period of approximately 2.3 years.

~~Table of Contents~~

Performance Stock Units

Stock-based compensation costs associated with the Company’s ~~performance~~restricted stock units subject to performance criteria (“PSUs”) are initially determined using the fair market value of the ~~Company's~~Company’s common stock on the date the awards are ~~approved by the Compensation Committee of the Board of Directors~~granted (service inception date). The vesting of these PSUs is subject to certain performance conditions and a service requirement ranging from 1one to 3three years. ~~Until the performance conditions are met, stock~~Stock-based compensation costs associated with these PSUs are re-assessed each reporting period based upon the estimated performance attainment on the reporting ~~date.~~date until the performance conditions are met. The ultimate number of PSUs that are issued to an employee is the result of the actual performance of the Company at the end of the performance period compared to the performance targets and generally r~~ange~~anges from ~~25%~~0% to 200% of the initial grant. Stock compensation expense for PSUs is recognized on an accelerated tranche by tranche basis for performance-based awards. ~~Forfeitures are accounted for at~~

PSU activity under the ~~time they occur consistent with Company policy.~~

~~Activity under PSUs~~Plans was as follows:


		Weighted-Average			Weighted-Average
		Grant Date			Grant Date
	Shares	Fair Value Per PSU		Shares	Fair Value Per PSU
Balance at December 31, 2021	356,249	$	140.01
Balance at December 31, 2022				629,672	$	99.07
Granted	420,274	$	74.21	1,127,045	$	26.88
Vested and issued	(197,849)	$	109.03	(108,775)	$	153.57
Balance at March 31, 2022	578,674	$	106.35
Vested and unissued at March 31, 2022	0	$	0
Non-vested at March 31, 2022	578,674	$	106.35
Forfeited				(5,999)	$	88.78
Performance adjustment (1)				(283,282)	$	79.12
Balance at March 31, 2023				1,358,661	$	39.03
Vested and unissued at March 31, 2023				0	$	0.00
Non-vested at March 31, 2023				1,358,661	$	39.03

(1) Based on the Company's 2022 results, performance stock units were attained at rates ranging from 0% to 86.25% of the target award.

Table of Contents

The total grant-date fair value of PSUs granted during the ~~quarter~~quarters ended March 31, 2023 and 2022 ~~and 2021~~ was ~~$30.1~~$30.3 million and ~~$67.9~~$30.1 million, respectively.

For the quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, the Company recorded stock-based compensation expense related to PSUs of ~~$7.3~~$3.4 million and ~~$7.2~~$7.3 million, respectively.

As of March 31, ~~2022,~~2023, the Company had ~~$26.9~~$44.2 million in unrecognized compensation cost related to non-vested PSUs, which is expected to be recognized over a weighted-average period of approximately ~~2.3~~2.0 years.

Employee Stock Purchase Plan

In July 2015, the Company adopted the 2015 Employee Stock Purchase Plan (“ESPP”) in connection with its initial public offering. A total of ~~1,019,726~~1,113,343 shares of common stock were reserved for issuance under this plan as of March 31, ~~2022.~~2023. The Company’s ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Under the ESPP, the Company may specify offerings with durations of not more than 27 months and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of its common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or on the date of purchase.

During the quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, the Company did not issue any shares under the ESPP. As of March 31, ~~2022, 570,661~~2023, 393,089 shares remained available for issuance.

For the quarters ended March 31, ~~2022~~2023 and ~~2021,~~2022, the Company recorded stock-based compensation expense related to the ESPP of $1.6 million and $1.5 million, ~~and $2.2 million,~~ respectively.

As of March 31, ~~2022,~~2023, the Company had ~~$0.6~~$0.7 million in unrecognized compensation cost related to the ESPP, which is expected to be recognized over a weighted-average period of approximately 0.1 year.

Total compensation costs for stock-based awards were recorded as follows (in thousands):


	Quarter Ended
	March 31,
	2023		2022
Cost of revenue (exclusive of depreciation and amortization, which is shown separately)	$	1,353	$	2,196
Advertising and marketing		3,126		3,711
Sales		8,075		12,071
Technology and development		12,729		18,087
General and administrative		20,755		24,371
Total stock-based compensation expense (1)	$	46,038	$	60,436

(1) Excludes the amount capitalized related to internal software development projects.

In the quarter ended March 31, 2023, the Company reversed $4.5 million of share-based compensation expense associated with individuals terminated under its restructuring plans. See Note 13, "Restructuring," for further information.

Note 15. Provision for Income Taxes

The Company’s provision for income taxes was an expense of $0.7 million for the quarter ended March 31, 2023 and $0.4 million for the quarter ended March 31, 2022. The tax expense for both quarters was primarily the result of the tax shortfall associated with the stock-based compensation awards that vested in the quarter.

Table of Contents

Note 16. Legal Matters

From time to time, Teladoc Health is involved in various litigation matters arising in the normal course of business, including the matters described below. The Company consults with legal counsel on those issues related to litigation and seeks input from other experts and advisors with respect to such matters. Estimating the probable losses or a range of probable losses resulting from litigation, government actions, and other legal proceedings is inherently difficult and requires an extensive degree of judgment, particularly where the matters involve indeterminate claims for monetary damages, may involve discretionary amounts, present novel legal theories, are in the early stages of the proceedings, or are subject to appeal. Whether any losses, damages, or remedies ultimately resulting from such matters could reasonably have a material effect on the Company’s business, financial condition, results of operations, or cash flows will depend on a number of variables, including, for example, the timing and amount of such losses or damages (if any) and the structure and type of any such remedies. As of the date of these financial statements, Teladoc Health’s management does not expect any litigation matter to have a material adverse impact on its business, financial condition, results of operations, or cash flows.

On August 27, 2021, a purported securities class action complaint (City of Hialeah Employees’ Retirement System v. Teladoc Health, Inc., et.al.) was filed in the Circuit Court of Cook County, Illinois against the Company and certain of the Company’s current and former officers and directors. The complaint was brought on behalf of a purported class consisting of all persons who acquired shares of Teladoc Health common stock issued in the Livongo merger. The complaint asserted violations of Sections 11, 12(a)(2) and 15 of the Securities Act based on allegedly false or misleading statements and omissions with respect to the registration statement and prospectus filed in connection with the Livongo merger. The complaint sought certification as a class action, unspecified compensatory damages plus interest and attorneys’ fees, rescission or a rescissory measure of damages and equitable or other relief. On January 18, 2022, the case was voluntarily dismissed without prejudice in the Circuit Court of Cook County, Illinois and on January 26, 2022, was refiled in the Supreme Court of the State of New York. The refiled case includes substantially the same allegations. The Company believes that these claims are without merit, and the Company and its named current and former officers and directors intend to defend the lawsuit vigorously, including through the filing of a motion to dismiss the complaint on April 8, 2022.

On June 6, 2022, a purported securities class action complaint (Schneider v. Teladoc Health, Inc., et. al.) was filed in the U.S. District Court for the Southern District of New York against the Company and certain of the Company’s officers. The complaint was brought on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period October 28, 2021 through April 27, 2022. The complaint asserted violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder based on allegedly false or misleading statements and omissions with respect to, among other things, the Company’s business, operations, and prospects. The complaint seeks certification as a class action and unspecified compensatory damages plus interest and attorneys’ fees. On August 2, 2022, a duplicative purported securities class action complaint (De Schutter v. Teladoc Health, Inc., et.al.) was filed in the U.S. District Court for the Eastern District of New York. The claims and parties in De Schutter were substantially similar to those in Schneider. The De Schutter case was transferred on consent to the Southern District court, and the Schneider and De Schutter actions have now been consolidated under the caption In re Teladoc Health, Inc. Securities Litigation. On August 23, 2022, the court appointed Leadersel Innotech ESG as lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. The lead plaintiff filed an amended complaint on September 30, 2022, on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period February 24, 2021 to July 27, 2022, and filed a second amended complaint on December 6, 2022, on behalf of a purported class consisting of all persons or entities who purchased or otherwise acquired shares of the Company’s common stock during the period February 11, 2021 to July 27, 2022. The Company believes that these claims are without merit, and the Company and its named officers intend to defend the lawsuit vigorously, including through the filing of a motion to dismiss the complaint on January 20, 2023.

On August 9, 2022, a verified shareholder derivative complaint (Vaughn v. Teladoc Health, Inc., et.al.) was filed in the U.S. District Court for the Southern District of New York against the Company as a nominal defendant and certain of the Company’s officers and directors. The complaint asserts violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, and waste of corporate assets in connection with factual assertions similar to those in the purported securities class action complaints described above. The complaint seeks damages to the Company allegedly sustained as a result of the acts and omissions of the named officers and directors and seeks an order directing

Table of Contents

the Company to reform and improve the Company’s corporate governance. On September 6, 2022, a duplicative verified stockholder derivative complaint (Hendry v. Teladoc Health, Inc., et. al) was filed in the U.S. District Court for the Southern District of New York. The claims and parties in Hendry were substantially similar to those in Vaughn. The Vaughn and Hendry actions have now been consolidated under the caption In re Teladoc Stockholder Derivative Litigation, and a consolidated complaint was filed on November 29, 2022. The consolidated complaint also asserts violations of Section 14(a) of the Securities Exchange Act of 1934. The parties subsequently stipulated to transfer the action to the U.S. District Court for the District of Delaware, and on December 22, 2022 the parties agreed, and the Court ordered, to stay all proceedings until final resolution, including exhaustion of appeals, of the motion to dismiss filed in the purported securities class action complaint described above.

On July 30, 2020, the Company received a Civil Investigative Demand from the Federal Trade Commission (“FTC”) as part of its non-public investigation to determine whether the Company, through its BetterHelp business, engaged in unfair business practices in violation of the Federal Trade Commission Act (the “FTC Investigation”). The Company subsequently entered into settlement negotiations with the FTC in an effort to resolve all claims and allegations arising out of or relating to the FTC Investigation. During 2022, the Company determined that a loss stemming from the FTC Investigation in the amount of $7.8 million is probable. In March 2023, the Company and the FTC entered into a settlement, pending federal court approval, and agreed to a consent order, that will require the Company to make a $7.8 million payment to the FTC.

There have been multiple putative class-action litigations filed against BetterHelp in relation to the allegations detailed in the FTC’s consent order described above, in both California state court and U.S. federal court in California. The cases are substantially similar, involving allegations of misleading patients as to BetterHelp’s use of patient data and associated alleged violations of law involving privacy, advertising, contract and tort. The Company believes that these claims are without merit, and the Company intends to defend the lawsuits vigorously.

Note 17. Segments

ASCSubtopic280-10,“SegmentReporting,” establishesstandardsforreportinginformation about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and assess performance. The Company’s Chief Executive Officer is the CODM and is responsible for reviewing financial information presented on asegmentbasisforpurposes ofmakingoperatingdecisions andassessingfinancialperformance.

The CODM measures and evaluates segments based on segment operating revenues together with Adjusted EBITDA.The Company excludes the following items from segment Adjusted EBITDA: provision for income taxes; other income, net; interest (income) expense, net; depreciation and amortization; goodwill impairment; loss on extinguishment of debt; stock-based compensation; restructuring costs; and acquisition, integration and transformation charges.Althoughtheseamounts are excludedfromsegmentAdjustedEBITDA,theyareincludedinreported consolidated net loss and are included in the reconciliation that follows.

The Company’scomputationofsegmentAdjustedEBITDAmaynotbecomparableto othersimilarly titled metrics computedby othercompanies becauseallcompanies do notcalculate segment Adjusted EBITDAin the same fashion.

Operating revenues and expenses directly associated with each segment are included in determining its operatingresults. Otherexpensesthat arenotdirectlyattributabletoaparticularsegmentarebaseduponallocation methodologies, including the following: revenue,headcount, time and other relevantusagemeasures, and/or a combination of such.

The Company has two reportable segments: Teladoc Health Integrated Care and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual mental health and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis. Other reflects certain revenues and charges not related to ongoing segment operations.

The CODM does not review any information regarding total assets on a segmentbasis.Segments do not record

Table of Contents

~~Total compensation costs~~intersegment revenues, and, accordingly, there is none to be reported. The accounting policies for ~~stock-based awards~~segment reporting are the same as for the Company as a whole.

The following table presents revenues by segment (in thousands):


	Quarter Ended
	March 31,
	2023		2022
Teladoc Health Integrated Care	$	349,972	$	332,384
BetterHelp		279,272		230,174
Other (1)		0		2,792
Total Consolidated Revenue	$	629,244	$	565,350

The following table presents Adjusted EBITDA by segment (in thousands):


	Quarter Ended
	March 31,
	2023		2022
Teladoc Health Integrated Care	$	35,127	$	23,267
BetterHelp		17,638		30,098
Other (1)		0		1,132
Total Consolidated Adjusted EBITDA	$	52,765	$	54,497

(1)

Other reflects certain revenues and expenses not related to ongoing segment operations.

The following table presents a reconciliation of segment Adjusted EBITDA to consolidated GAAP income before income taxes (in thousands):


	Quarter Ended
	March 31,
	2023		2022
Teladoc Health Integrated Care	$	35,127	$	23,267
BetterHelp		17,638		30,098
Other		0		1,132
Total consolidated Adjusted EBITDA		52,765		54,497
Adjustments to reconcile to GAAP net loss
Goodwill impairment		0		(6,600,000)
Other income, net		4,907		724
Interest income (expense), net		3,648		(5,480)
Depreciation and amortization		(69,783)		(58,933)
Stock-based compensation		(46,038)		(60,436)
Acquisition, integration, and transformation costs		(5,944)		(4,507)
Restructuring costs		(8,102)		0
Loss before provision for income taxes		(68,547)		(6,674,135)
Provision for income taxes		(681)		(388)
Net loss	$	(69,228)	$	(6,674,523)

Geographic data for long-lived assets (representing property, plant and equipment) were ~~recorded~~ as follows (in thousands):

Quarter Ended

March 31,


2022

2021



Cost of revenue (exclusive of depreciation and amortization, which is shown separately)

$
2,196

$
2,362

Advertising and marketing

3,711

5,082

Sales

12,071

21,167

Technology and development

18,087

26,726

General and administrative

24,371

30,963

Total stock-based compensation expense (1)

$
60,436

$
86,300

~~(1)~~

~~Excluding the amount capitalized related to internal software development projects.~~


	As of March 31,		As of December 31,
	2023		2022
United States	$	25,957	$	25,935
Other		3,834		3,706
Total long-lived assets	$	29,791	$	29,641

~~Note 15. Income Taxes~~

~~The Company recorded income tax expense of $0.4 million for the quarter ended March 31, 2022.~~

For the quarter ended March 31, 2022, the Company recognized a reversal of $15.3 million of the net deferred tax liability associated with the convertible senior notes upon the adoption of ASU 2020-06, recorded entirely through the balance sheet.

The Company’s income tax expense for the quarter ended March 31, 2021 of $87.0 million primarily was related to additional valuation allowance recorded on excess stock compensation associated with the Livongo merger.

2122

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Special Note Regarding Forward-Looking Statements

Many statements made in this Quarterly Report on Form 10-Q that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipates,” “believes,” “suggests,” “targets,” “projects,” “plans,” “expects,” “future,” “intends,” “estimates,” “predicts,” “potential,” “may,” “will,” “should,” “could,” “would,” “likely,” “foresee,” “forecast,” “continue” and other similar words or phrases, as well as statements in the future tense to identify these forward-looking statements. These forward-looking statements and projections are contained throughout this Form 10-Q, including the section entitled” “Management’s Discussion and Analysis of Financial Condition and Results of ~~Operations” (“MD&A”).~~Operations.” We base these forward-looking statements or projections on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances and at such time. As you read and consider this Form 10-Q, you should understand that these statements are not guarantees of performance or results. The forward-looking statements and projections are subject to and involve risks, uncertainties, and assumptions and you should not place undue reliance on these forward-looking statements or projections. Although we believe that these forward-looking statements and projections are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those expressed in the forward-looking statements and projections. Factors that may materially affect such forward-looking statements and projections include, but are not limited to, the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 (the ~~“2021~~“2022 Form 10-K”) and in our other reports and ~~United States (“~~U.S.”) Securities and Exchange Commission (“SEC”) filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this Form 10-Q. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should evaluate all forward-looking statements made in this Form 10-Q in the context of these risks and uncertainties.

Overview

Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” the “Company,” or “we.” The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in whole person virtual care ~~focused~~focusing on forging a new healthcare experience with better convenience, outcomes, and value around the world.

Teladoc Health was founded on a simple, yet revolutionary idea: that everyone should have access to the best healthcare, anywhere in the world on their terms. Today, we have a vision of making virtual care the first step on any healthcare journey, and we are delivering on this mission by providing whole person virtual care that includes primary care, mental health, chronic condition management, and more.

~~COVID-19 Update~~

We believe that favorable existing secular trends in the healthcare industry were accelerated by the impacts of the COVID-19 pandemic, driving greater consumer use of virtual care, and increased adoption by employers, health plans, hospitals and health systems, and healthcare providers. In combination with the expansion of our capabilities, we believe that these trends present significant opportunities for virtual healthcare to address the most pressing, universal healthcare challenges through trusted solutions, such as ours, that deliver convenient, affordable, and high-quality care; empower individuals to manage and improve their health; and enable providers to offer their best care for their patients.

We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business. COVID-19 has increased utilization of our telehealth services, but it is uncertain whether such increase in demand will continue. While the COVID-19 pandemic has not had a material adverse impact on our financial condition and results of operations to date, the future impact on our operational and financial performance will depend on certain developments, including the duration and spread of the pandemic, impact on our customers, consisting of employers, health plans,

~~Table of Contents~~

hospitals and health systems, insurance, and financial services companies (collectively “Clients”), and members, impact on our sales cycles, and effect on our vendors, all of which are uncertain and cannot be predicted. Public and private sector policies and initiatives to reduce the transmission of COVID-19 and disruptions to our operations and the operations of our third-party suppliers, along with any related global slowdown in economic activity, may result in decreased revenues, decreased collections, and increased costs. Further, the economic effects of the COVID-19 pandemic have financially constrained some of our prospective and existing Clients’ healthcare spending, which may negatively impact our ability to acquire new Clients and our ability to renew subscriptions with or sell additional solutions to our existing Clients. We also may experience increased member attrition to the extent our existing Clients reduce their respective workforces in response to economic conditions. In addition, due to our subscription-based business model, the effect of the COVID-19 pandemic may not be fully reflected in our revenue until future periods. It is possible that the COVID-19 pandemic, the measures taken by the governments and businesses affected and any resulting economic impact may materially and adversely affect our business, results of operations, cash flows, and financial positions as well as our customers.

We have also taken measures in response to the COVID-19 pandemic, and we may take further actions that alter our business operations as may be required by federal, state, local, or foreign authorities or that we determine are in the best interests of our employees, Clients, members, and stockholders. The effects of these operational modifications are unknown and may not be realized until further reporting periods.

~~Acquisition History~~

We have scaled and intend to continue to scale our platform through the pursuit of selective acquisitions. We have completed multiple acquisitions since our inception, which we believe have expanded our distribution capabilities and broadened our service offerings.

On October 30, 2020, we completed the merger with Livongo. The total final consideration was $13,876.9 million, consisting of $380.2 million of net cash, $555.4 million related to the conversion feature of the Livongo Notes guaranteed by the Company and 60.2 million shares of Teladoc Health’s common stock valued at approximately $12,941.3 million on October 30, 2020. Livongo is a leading provider to empower people with chronic conditions to live better and healthier lives.

On July 1, 2020, we completed the acquisition of InTouch for aggregate consideration of $1,069.8 million, which was comprised of 4.6 million shares of our common stock valued at $903.3 million on July 1, 2020, and $166.5 million of net cash. InTouch is a leading provider of enterprise telehealth solutions for hospitals and health systems.

~~Net Income~~

For the quarter ended March 31, 2022, we recorded a loss of $6,674.5 million or $41.58 per share. The quarter included a non-cash goodwill impairment charge of $6,600.0 million. Refer to Critical Accounting Estimates and Policies: Goodwill Impairment Charge and Note 7, Goodwill, to the Company’s condensed consolidated financial statements for more information.

~~For the quarter ended March 31, 2021, we recorded a loss of $199.6 million.~~

~~Refer to the condensed consolidated results of operations in the MD&A for other supplemental financial measures we use to assess our operating performance.~~

Key Factors Affecting Our Performance

We believe that our future performance will depend on many factors, including the following:

As it relates to the Integrated Care segment:

Number of ~~Members~~U.S. Integrated Care Members. U.S. Integrated Care members represent the number of unique individuals who have paid access and ~~Revenue per Member.~~visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period. Our revenue growth rate and long-term profitability are affected by our ability to increase cross selling capability among our existing members over time because we derive a substantial portion of our revenue from access and other fees via Client contracts that provide members access to our professional provider network in exchange for a contractual based periodic ~~fee or access fees derived from our Direct-to-Consumer (“D2C”) members.~~fee. Therefore, we believe that our ability to add new members and retain existing members, and to increase ~~the revenue generated from each member~~utilization and penetration further into existing and new health plan Clients is a key indicator of our increasing market adoption, the growth of our business, and our future revenue potential. We further believe that

Table of Contents

~~and future revenue potential, and that~~ increasing our membership ~~and revenue per member~~ is an integral objective that will provide us with the ability to continually innovate our services and support initiatives that will enhance members’ experiences. U.S. ~~paid membership~~Integrated Care members increased by ~~2.7~~5.7 million to ~~54.3~~84.9 million at March 31, ~~2022,~~2023, compared to the same period in 2021. Average U.S. revenue per member measures the average amount of access revenue that we generate from a U.S. paid member for a particular period. It is calculated by dividing the U.S. access revenue generated from our U.S. paid members, excluding certain non-member based access fees, by the total average number of U.S. paid members during the applicable period. For the first quarter of 2022, average U.S. revenue per member was $2.52 compared to $2.09 for the same period in 2021.

~~Number of Visits and Utilization.~~ We also recognize revenue in connection with the completion of a general medical visit, expert medical service, and other specialty visits for contracts where the service is not part of access fees. Visit fee revenue is driven primarily by the number of Clients, the number of members in a Client’s population, member utilization of our provider network services and the contractually negotiated prices of our services. We believe that increasing our current member utilization rate and increasing penetration further into existing and new health plan Clients is a key objective in order for our Clients to realize tangible healthcare savings with our service. Visits increased by 35%, or 1.2 million, to approximately 4.5 million for the quarter ended March 31, 2022 compared to the same period in 2021. Utilization measures the ratio of visits to total U.S. paid members. It is calculated by dividing visits during a particular period (excluding visit fee only visits) by U.S. paid members in the applicable period and annualizing the result. Utilization increased by 593 basis points to approximately 23.4% for the quarter ended March 31, 2022, compared to 17.5% in the same period in 2021.

~~Number of Platform-Enabled Sessions.~~ A platform-enabled session is a unique instance in which our licensed software platform has facilitated a virtual voice or video encounter between a care provider and our Client’s patient, or between care providers. We believe platform-enabled sessions are an indicator of the value our Clients derive from the platform they license from us in order to facilitate virtual care. Our Clients completed 1.2 million platform-enabled sessions during the quarter ended March 31, 2022, compared to 1.1 million during the same period in 2021.2022.

Chronic Care ~~Enrollment.~~ Program Enrollment. Chronic care program enrollment represents the total of enrollees across our suite of chronic care programs at the end of a given period. Our chronic care ~~programs~~program enrollments are one of the key components of our whole person virtual care platform that we believe ~~position~~positions us to drive greater engagement with our platforms and increased revenue. Chronic care ~~enrollment measures the number of unique individuals enrolled in one or more of our chronic care programs. Chronic care~~program enrollment increased by ~~12%~~13% to ~~0.7~~1.03 million at March 31, ~~2022,~~2023, compared to ~~0.7~~0.91 million at March 31, ~~2021.~~2022.

Average Revenue Per U.S. Integrated Care Member. Average revenue per U.S. Integrated Care member measures the average amount of global revenue that we generate from a U.S. Integrated Care member for a particular period. It is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care members during the applicable period. Approximately 20% of total Integrated Care revenues relates to international and hospital and health systems for which membership is not considered as a management metric. We believe that our ability to increase the revenue generated from each member over time is also a key indicator of our increasing market adoption, the growth of our business, and future revenue potential. Average revenue per U.S. Integrated Care member decreased to $1.39 in the quarter ended March 31, 2023, from $1.41 in the same period in 2022, primarily due to the impact of new members onboarded over the course of the year.

As it relates to the BetterHelp segment:

BetterHelp Paying Users. BetterHelp paying users represent the average number of global monthly paying users of our BetterHelp therapy services during the applicable period. We believe that our ability to add new paying users and retain existing users is a key indicator of the increasing market adoption of BetterHelp, the growth of that business, and future revenue potential. Our ability to efficiently reach new potential paying users through various advertising channels helped us to increase BetterHelp paying users by 22% to 0.47 million as of March 31, 2023, compared to 0.38 million as of March 31, 2022.

As it relates to the Company:

Seasonality. We Our business has historically been subject to seasonality. In our Integrated Care segment, as a result of many Clients’ introduction of new services at the start of each year, a concentration of our new Client contracts has an effective date of January 1. Therefore, while membership increases, utilization and enrollment rates are dampened until service delivery ramps up over the course of the year. As a result of seasonal cold and flu trends, we historically have ~~typically in the past seen the strongest increases in consecutive quarterly~~experienced our highest level of visit and other fee revenue during the ~~fourth~~first and ~~first~~fourth quarters of each ~~year, which coincides with traditional annual benefit enrollment seasons. However, as~~ year.

Due to the higher cost of customer acquisition during the end-of-year holiday season, our ~~business~~BetterHelp segment has ~~become more diversified across services, channels,~~historically reduced marketing activity during the fourth quarter. As a result of this dynamic we have typically experienced fewer new member additions and geographies, we see a growing diversification of Client start dates, resulting from growth in mental health offerings, health plan expansions, cross sales of new services, international growth, and mid-market employer growth, all of which are not constrained by a calendar year start. See “Risk Factors—Risks Related to Our Business—Our quarterly results may fluctuate significantly, which could adversely impact the ~~value of our common stock” included~~strongest operating income performance in the ~~2021 Form 10-K.~~fourth quarter. Conversely, as marketing activity typically resumes at the start of the year, we typically experience the weakest operating income performance during the first quarter as new customer acquisition and revenue growth lags marketing spend.

Critical Accounting Estimates and Policies

Our discussion and analysis of our results of operations, liquidity and capital resources are based on our condensed consolidated financial statements which have been prepared in conformity with accounting principles generally accepted in the U.S. (“GAAP”). The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities.

~~Table of Contents~~

On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, business combinations, goodwill and other intangible assets, income taxes, and other items. We base our estimates on historical and anticipated results and trends and on various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. By their nature, estimates are

Table of Contents

subject to an inherent degree of uncertainty. Actual results may differ from our estimates and could have a significant adverse effect on our results of operations and financial position. For a discussion of our critical accounting policies and estimates see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the ~~2021~~2022 Form 10-K. In addition, the following updates our discussion of impairment testing therein as of March 31, ~~2022.~~2023.

Goodwill Impairment Charge

~~As a result of sustained decreases~~In March 2022, we performed an impairment assessment using updated forecasted future cash flows, including revenues, margin, and capital expenditures to reflect current conditions. In addition, we changed other valuation assumptions, including increases in ~~our publicly quoted share price~~interest rates and market ~~capitalization continuing into 2022, we conducted additional testing~~volatility, resulting in a higher discount rate than what was used previously, and a selection of ~~our goodwill, definite-lived intangibles and other long-lived assets as~~lower revenue multiples based upon an assessment of ~~March 31, 2022.~~a relevant peer group. As a result of this review, we did not identify an impairment to our definite-lived intangible assets or other long-lived assets, but we recorded a $6.6 billion non-deductible ~~non-cash~~ goodwill impairment charge (or $41.11 per basic and diluted share) for the quarter ended March 31, 2022. The non-cash impairment charge had no impact on the provision for income taxes.

~~Consistent with prior~~There were no impairment charges recorded for goodwill ~~impairment testing, our~~or definite-lived intangible assets for the quarter ended March 31, 2023. As of the October 1, 2022 testing ~~reflected a 75%/25% allocation between~~period, the income and market approaches. We believe the 75% weighting to the income approach continues to be appropriate as it more directly reflects our future growth and profitability expectations. For our March 31, 2022 impairment testing, as compared to our December 1, 2021 testing, we reduced our estimated future cash flows used in the impairment assessment, including revenues, margin, and capital expenditures to reflect our best estimates at this time. We also updated certain significant inputs into the valuation models including the discount rate which increased reflecting, in part, higher interest rates and market volatility, and we reduced our revenue market multiples, reflecting declining valuations across our selected peer group. Our updates to our discount rate, market multiples, and estimated future cash flows each had a significant impact to the estimated fair value of our reporting unit.

~~The following table indicates changes in the most significant inputs to our impairment analysis on each testing date since our last annual test.~~

Overall, in the event there are future adverse changes in our estimated future cash flows and/or changes in key assumptions, including but not limited to discount rate increases, lower market multiples, lower revenue growth, lower margin, and/or a lower terminal growth rate, we may be required to record additional non-cash impairment charges to our goodwill, or impairment charges to other intangibles, and/or long-lived assets. Such non-cash charges would likely have a material adverse effect on our consolidated statements of operations and balance sheets in the reporting period of the charge. Following the March 2022 impairment there is no excess of reporting unit ~~fair~~ value over ~~the~~ carrying ~~amount, so any further decrease in estimated fair~~ value ~~would result in an additional goodwill impairment charge.~~

In the period following March 31, 2022 there has been a further decline in our market capitalization, based on our publicly quoted share price. To the extent the decline is sustained, it would require further testing of our goodwill in our next reporting period and it may result in an additional goodwill impairment. Absent further changes to our estimated future cash flows, it may prompt updates to other key valuation inputs, including the discount rate and market multiples. Further reductions in estimated future cash flows could also result in an additional decline in estimated reporting unit value. As an illustration, if the estimated fair value of the reporting unit at March 31, 2022, decreased by 50%, it would result in a goodwill impairment charge of approximately $4.6 billion.

~~Table of Contents~~

~~Condensed Consolidated Results of Operations~~

~~The following table sets forth our condensed consolidated statement of operations data~~was significant for the ~~quarters ended March 31, 2022 and 2021 and the dollar and percentage change between the respective periods (dollars in thousands except for per share data):~~remaining goodwill.

Quarter Ended March 31,

Year over Year Growth

2022

2021


Variance

%

Revenue

$
565,350

$
453,675

$
111,675

25
%

Expenses:

Cost of revenue (exclusive of depreciation and amortization,
which is shown separately below)

187,025

145,959

41,066

28
%

Operating expenses:

Advertising and marketing

133,600

89,439

44,161

49
%

Sales

58,329

64,793

(6,464)

(10)
%

Technology and development

87,412

78,008

9,404

12
%

General and administrative

104,923

105,172

(249)

0
%

Acquisition, integration, and transformation costs

4,507

6,323

(1,816)

(29)
%

Depreciation and amortization

58,933

48,659

10,274

21
%

Goodwill impairment

6,600,000

0

6,600,000

N/M

Total expenses

7,234,729

538,353

6,696,376

N/M

Loss from operations

(6,669,379)

(84,678)

(6,584,701)

N/M

Loss on extinguishment of debt

0

11,459

(11,459)

(100)
%

Other income, net

(724)

(5,652)

4,928

(87)
%

Interest expense, net

5,480

22,125

(16,645)

(75)
%

Net loss before taxes

(6,674,135)

(112,610)

(6,561,525)

N/M

Income tax expense

388

87,039

(86,651)

(100)
%

Net loss

$
(6,674,523)

$
(199,649)

$
(6,474,874)

N/M

Net loss per share, basic and diluted

$
(41.58)

$
(1.31)

$
(40.27)

N/M

EBITDA (1)

$
(10,446)

$
(36,019)

$
25,573

(71)
%

Adjusted EBITDA (1)

$
54,497

$
56,604

$
(2,107)

(4)
%

~~(1)~~

~~Non-GAAP Financial Measures~~

~~N/M – not meaningful~~

~~Table of Contents~~

~~The following is a reconciliation of net loss, the most directly comparable U.S. GAAP financial measure, to EBITDA and Adjusted EBITDA for the quarters ended March 31, 2022 and 2021 (in thousands):~~

Quarter Ended

March 31,


2022

2021


Net loss

$
(6,674,523)

$
(199,649)

Add:

Goodwill impairment

6,600,000

0

Loss on extinguishment of debt

0

11,459

Other income, net

(724)

(5,652)

Interest expense, net

5,480

22,125

Income tax expense

388

87,039

Depreciation and amortization

58,933

48,659

EBITDA

(10,446)

(36,019)

Stock-based compensation

60,436

86,300

Acquisition, integration, and transformation costs

4,507

6,323

Adjusted EBITDA

$
54,497

$
56,604

EBITDA and Adjusted EBITDA

To supplement our financial information presented in accordance with ~~U.S.~~ GAAP, we use earnings before interest, provision for income taxes, depreciation, and amortization (“EBITDA”) ~~and~~, Adjusted EBITDA, and free cash flow which are ~~non-U.S. GAAP~~non-GAAP financial measures, to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize Adjusted EBITDA as ~~the primary~~a key measure of our performance.

EBITDA consists of net loss before ~~interest;~~interest (income) expense, net; other income, net, including foreign exchange gain or loss; provision for income taxes; depreciation and amortization; and goodwill ~~impairment; and loss on extinguishment of debt.~~impairment. Adjusted EBITDA consists of net loss before ~~interest;~~interest (income) expense, net; other income, net, including foreign exchange gain or loss; provision for income taxes; depreciation and amortization; goodwill impairment; ~~loss on extinguishment of debt;~~ stock-based compensation; restructuring costs; and acquisition, integration, and transformation costs.

Free cash flow is net cash (used in) provided by operating activities less capital expenditures and capitalized software development costs. We believe that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows.

We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms EBITDA, ~~and~~ Adjusted EBITDA and free cash flow may vary from that of others in our industry. Neither EBITDA, ~~nor~~ Adjusted EBITDA nor free cash flow should be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other performance measures derived in accordance with ~~U.S.~~ GAAP.

EBITDA, ~~and~~ Adjusted EBITDA, and free cash flow have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under ~~U.S.~~ GAAP. Some of these limitations are:

●

EBITDA and Adjusted EBITDA do not reflect goodwill impairment;

●

EBITDA and Adjusted EBITDA do not reflect the interest (income) expense, ~~on our debt;~~net;

Table of Contents

●

EBITDA and Adjusted EBITDA eliminate the impact of the provision for income taxes on our results of operations;

●

~~EBITDA and Adjusted EBITDA do not reflect the loss on extinguishment of debt;~~

●

EBITDA and Adjusted EBITDA do not reflect other income, net;

●

Adjusted EBITDA does not reflect ~~the~~restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;

●

Adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration and certain other transaction

~~Table of Contents~~

costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our customer relationship management (“CRM”) and enterprise resource planning (“ERP”) systems. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities;

●

Adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and

●

~~other~~Other companies in our industry may calculate EBITDA, and Adjusted EBITDA differently than we do, limiting the usefulness of these measures as comparative measures.

In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and both EBITDA and Adjusted EBITDA do not reflect any expenditures for such replacements.

We compensate for these limitations by using EBITDA, ~~and~~ Adjusted EBITDA, and free cash flow along with other comparative tools, together with ~~U.S.~~ GAAP measurements, to assist in the evaluation of operating performance. Such ~~U.S.~~ GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.

In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of EBITDA, ~~and~~ Adjusted EBITDA, and free cash flow should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

Table of Contents

Condensed Consolidated Results of Operations

The following table sets forth our condensed consolidated statement of operations data for the quarters ended March 31, 2023 and 2022 and the dollar and percentage change between the respective periods (dollars in thousands except for per share data):


	Quarter Ended March 31,
	2023		2022
	$		$			Variance	%
Revenue	$	629,244	$	565,350	$	63,894	11	%
Cost of revenue		190,107		187,025		3,082	2	%
Gross profit		439,137		378,325		60,812	16	%
Expenses:
Cost of revenue (exclusive of depreciation and amortization, which is shown separately below)		190,107		187,025		3,082	2	%
Operating expenses:
Advertising and marketing		176,790		133,600		43,190	32	%
Sales		54,490		58,329		(3,839)	(7)	%
Technology and development		86,985		87,412		(427)	(0)	%
General and administrative		114,145		104,923		9,222	9	%
Acquisition, integration, and transformation costs		5,944		4,507		1,437	32	%
Restructuring costs		8,102		0		8,102	n/m
Depreciation and amortization		69,783		58,933		10,850	18	%
Goodwill impairment		0		6,600,000		(6,600,000)	n/m
Loss from operations		(77,102)		(6,669,379)		6,592,277	99	%
Other income, net		(4,907)		(724)		(4,183)	n/m	%
Interest (income) expense, net		(3,648)		5,480		(9,128)	167	%
Loss before provision for income taxes		(68,547)		(6,674,135)		6,605,588	99	%
Provision for income taxes		681		388		293	76	%
Net loss	$	(69,228)	$	(6,674,523)	$	6,605,295	99	%
Net loss per share, basic and diluted	$	(0.42)	$	(41.58)	$	41.16	99	%

EBITDA (1)	$	(7,319)	$	(10,446)	$	3,127	30	%
Adjusted EBITDA (1)	$	52,765	$	54,497	$	(1,732)	(3)	%

n/m – not meaningful

(1)	Non-GAAP Financial Measures

Table of Contents

The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to EBITDA and Adjusted EBITDA for the quarters ended March 31, 2023 and 2022 (in thousands):


	Quarter Ended
	March 31,
	2023		2022
Net loss	$	(69,228)	$	(6,674,523)
Add:
Goodwill impairment		0		6,600,000
Other income, net		(4,907)		(724)
Interest (income) expense, net		(3,648)		5,480
Provision for income taxes		681		388
Depreciation and amortization		69,783		58,933
EBITDA		(7,319)		(10,446)
Stock-based compensation		46,038		60,436
Acquisition, integration, and transformation costs		5,944		4,507
Restructuring costs		8,102		0
Adjusted EBITDA	$	52,765	$	54,497

Teladoc Health Integrated Care	$	35,127	$	23,267
BetterHelp		17,638		30,098
Other		0		1,132
Adjusted EBITDA	$	52,765	$	54,497

Revenue. Total revenue was ~~$565.4~~$629.2 million for the quarter ended March 31, ~~2022,~~2023, compared to ~~$453.7~~$565.4 million during the quarter ended March 31, ~~2021,~~2022, an increase of ~~$111.7~~$63.9 million, or ~~25%~~11%. ~~This increase in revenue was driven substantially by the generation of additional~~Total access fees ~~by our membership base, most significantly from our D2C mental health service, BetterHelp. Revenue from access fees was~~were $550.9 million for the quarter ended March 31, 2023 compared to $491.3 million for the quarter ended March 31, 2022, ~~compared~~an increase of $59.5 million, or 12%. Other revenue, which predominately includes visit fees and, to ~~$382.1~~a lesser extent, revenues from the sales of our telehealth solutions for hospitals and health systems, was $78.4 million for the quarter ended March 31, ~~2021,~~2023 compared to $74.0 million for the quarter ended March 31, 2022, an increase of ~~$109.2~~$4.4 million, or ~~29%~~6%. Visit fee revenue increased 12% to $67.9 million and other revenue was $6.1 million, down 45% primarily related to the completion of a long-term development services contract. U.S. revenue grew 24% to $491.2 million and International revenue grew 27% to $74.2 million. For the quarter ended March 31, ~~2022, 87%,~~2023, 88% and 12% ~~and 1%~~ of our revenue was derived from access fees ~~visit fees~~ and other revenue, respectively, as compared to ~~84%,~~87% and 13% ~~and 3%~~, respectively, for the quarter ended March 31, ~~2021.~~2022. By geography, U.S. revenue grew 10% to $541.7 million and International revenue grew 18% to $87.6 million compared to the quarter ended March 31, 2022.

Cost of Revenue (exclusive of depreciation and amortization, which is shown separately below). Cost of revenue ~~(exclusive of depreciation and amortization, which is shown separately below)~~ was $190.1 million for the quarter ended March 31, 2023 compared to $187.0 million for the quarter ended March 31, 2022, ~~compared to $146.0~~an increase of $3.1 million, or 2%. The increase for the quarter ~~ended March 31, 2021, an increase of $41.1 million, or 28%. The increase~~ was primarily due to growth in visits associated with higher revenue ~~which resulted in increased provider fees, as well as higher device-related costs.~~partially offset by lower device costs amortization and various optimization efforts.

Advertising and Marketing Expenses. Advertising and marketing expenses were $176.8 million for the quarter ended March 31, 2023 compared to $133.6 million for the quarter ended March 31, 2022, ~~compared to $89.4~~an increase of $43.2 million, or 32%. The increase for the quarter ~~ended March 31, 2021, an increase of $44.2 million, or 49%. The increase~~ was substantially driven by higher digital and media advertising costs ~~from~~related to BetterHelp.

Sales Expenses. Sales expenses were $54.5 million for the quarter ended March 31, 2023 compared to $58.3 million for the quarter ended March 31, 2022, ~~compared to $64.8~~a decrease of $3.8 million, or 7%. The decrease for the quarter ~~ended March 31, 2021, a decrease of $6.5 million, or 10%. The decrease~~ was primarily driven by lower stock-based compensation and other employee related costs, partially offset by higher ~~sales~~commissions driven by increased revenues and ~~partner commissions due~~higher costs related to ~~higher results, as well as higher expense associated with~~sales conferences and ~~events to support business activity.~~events.

Technology and Development Expenses. Technology and development expenses were $87.0 million for the quarter ended March 31, 2023 compared to $87.4 million for the quarter ended March 31, 2022, ~~compared to $78.0 million for the~~a decrease of $0.4 million. The quarter ~~ended March 31, 2021, an increase of $9.4 million, or 12%. The increase primarily~~ reflects ~~additional~~lower stock-based compensation and lower recruiting expenses. Offsetting these costs were higher personnel ~~and staff augmentation costs; higher professional, recruiting and consulting fees;~~costs and higher infrastructure, hosting and software license ~~costs. These increases were~~costs associated with running operations and ongoing projects and services to continuously improve and optimize our ~~technology portfolio. Partially~~products and services. For the quarters ended March 31, 2023 and 2022, research and development costs, which exclude amounts reflected as capitalized software, were $30.4 million and $27.0 million, respectively.

Table of Contents

~~offsetting this increase was lower stock-based compensation. For~~

General and Administrative Expenses. General and administrative expenses increased $9.2 million, or 9%, to $114.1 million for the ~~quarters~~quarter ended March 31, ~~2022~~2023 compared to $104.9 million for the quarter ended March 31, 2022. The increase was driven by higher personnel costs and ~~2021, research~~higher therapist recruiting costs, partially offset by lower stock-based compensation and ~~development costs were $54.7 million and $53.4 million, respectively.~~other taxes.

Acquisition, Integration, and Transformation Costs. Acquisition, integration, and transformation costs were $5.9 million and $4.5 million for the ~~quarter~~quarters ended March 31, 2023 and 2022, respectively, and primarily consisted of ~~integration and transformation~~ costs to integrate and upgrade our CRM and ERP ecosystem. ~~For the quarter ended March 31, 2021, acquisition, integration and transformation~~

Restructuring Costs. Restructuring costs were ~~$6.3 million and primarily consisted of acquisition related costs.~~

~~General and Administrative Expenses.~~ ~~General and administrative expenses were essentially flat at $104.9~~$8.1 million for the quarter ended March 31, ~~2022 compared~~2023 primarily consisting of losses related to ~~$105.2 million~~early lease terminations and severance. See Note 13. “Restructuring” of the notes to the condensed consolidated financial statements for ~~the quarter ended March 31, 2021. Higher therapist recruiting~~additional information related to expected future costs ~~bank charges, legal fees, dues, subscriptions and licenses, and other corporate expenses were offset by lower stock-based compensation, insurance and bad debt expenses.~~to be incurred in 2023.

Depreciation and Amortization. Depreciation and amortization was $69.8 million for the quarter ended March 31, 2023 compared to $58.9 million for the quarter ended March 31, 2022, ~~compared to $48.7 million for the quarter ended March 31, 2021,~~ an increase of ~~$10.3 million.~~18%. The higher ~~expense was primarily due to additional~~ amortization ~~expense related to the acceleration of the amortization of certain trademarks, and to a lesser extent, higher amortization~~is associated with higher capitalized software development costs. As it relates to the acceleration of the useful lives for certain trademarks, this change related to the Company’s strategy to integrate and move certain consumer brands under the Teladoc Health brand. This acceleration of amortization resulted in decreasing the weighted average useful life of all trademarks at the date of the change from 9.5 years to 7.5 years. This change will increase annual amortization by approximately $23.0 million in 2022 and 2023.

Goodwill Impairment. ~~The Company took~~We did not record a non-cash goodwill impairment charges for the quarter ended March 31, 2023. In the prior year quarter ended March 31, 2022, we recorded a non-cash goodwill impairment charge of $6.6 billion, ~~in the quarter ended March 31, 2022,~~ following goodwill impairment ~~testing~~testings performed as a result of sustained decreases in our publicly quoted share price. The non-cash charge had no impact on the provision for income taxes. ~~Refer to Critical Accounting Estimates and Policies: Goodwill Impairment Charge and Note 7, Goodwill, to the Company’s condensed consolidated financial statements.~~

~~Loss on Extinguishment of Debt.~~ ~~There was no loss on extinguishment of debt for the quarter ended March 31, 2022 compared to $11.5 million for the quarter ended March 31, 2021.~~

Other Income, Net. Other income, net was ~~($0.7)~~an income of $4.9 million for the quarter ended March 31, 2023 compared to an income of $0.7 million for the quarter ended March 31, 2022 ~~compared to ($5.7) million for the quarter ended March 31, 2021 and included foreign exchange remeasurements. In addition, the quarter ended March 31, 2021 included~~primarily reflecting a ~~$5.9 million unrealized~~ gain on the partial sale of a ~~non-marketable equity security.~~business.

Interest (Income) Expense, Net. Interest (income) expense, net ~~consists~~consisted of ~~interest costs and amortization of debt discount associated with advances from financing companies, our convertible senior notes,~~ interest income from cash and cash equivalents and ~~short-term investments.~~interest costs and amortization of debt discount primarily associated with the convertible senior notes. Interest (income) expense, net was ~~$5.5~~an income of $3.6 million ~~and $22.1 million~~ for the quarters ended March 31, 2022 and 2021, respectively. The decrease in interest expense substantially reflects the adoption of ASU 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which resulted in the elimination of non-cash interest expense associated with the accretion of the recorded debt value to stated value. Refer to Note 11, Convertible Senior Notes, to the condensed consolidated financial statements. The associated non-cash expense was $14.6 million, or $0.10 per share, in the quarter ended March 31, ~~2021.~~2023 compared to an expense of $5.5 million for the quarter ended March 31, 2022. The increase was driven by higher interest income. Interest income was $8.9 million for the quarter ended March 31, 2023 compared to $0.2 million for the quarter ended March 31, 2022.

Provision for Income ~~Tax Expense~~Taxes. ~~Income~~We recorded an income tax expense ~~was~~of $0.7 million for the quarter ended March 31, 2023 compared to an expense of $0.4 million for the quarter ended March 31, 2022.

Segment Information

The following tables set forth the results of operations for the relevant segments for the quarters ended March 31, 2023 and 2022 ~~compared~~(dollars in thousands):


	Quarter Ended March 31,
Teladoc Health Integrated Care	2023				2022		Variance			%
Revenue	$	349,972		$	332,384		$	17,588		5	%
Adjusted EBITDA	$	35,127		$	23,267		$	11,860		51	%
Adjusted EBITDA Margin %		10.0	%		7.0	%		304	bps

Integrated Care total revenues increased by $17.6 million, or 5%, to ~~$87.0~~$350.0 million ~~expense~~ for the quarter ended March 31, 2021. The expense in the prior year quarter largely reflected an increase in valuation allowances needed to reflect the Company’s ability to utilize future net operating losses, primarily associated with stock compensation benefits associated with the Livongo merger.2023 on higher chronic care enrollment and adoption, as well as higher telemedicine product revenue, including higher revenues from our Primary 360 offering.

Integrated Care Adjusted EBITDA increased by $11.9 million, or 51%, to $35.1 million for the quarter ended March 31, 2023, primarily reflecting higher gross profit, partially offset by higher operating expenses, namely general administrative and technology and development expenses.

Table of Contents


	Quarter Ended March 31,
BetterHelp	2023				2022		Variance			%
Therapy Services	$	275,928		$	229,117		$	46,811		20	%
Other Wellness Services		3,344			1,057			2,287		216	%
Total Revenue	$	279,272		$	230,174		$	49,098		21	%
Adjusted EBITDA	$	17,638		$	30,098		$	(12,460)		(41)	%
Adjusted EBITDA Margin %		6.3	%		13.1	%		(676)	bps

BetterHelp total revenues increased by $49.1 million, or 21%, to $279.3 million for the quarter ended March 31, 2023, driven by a 22% increase in average monthly paying users.

BetterHelp Adjusted EBITDA decreased by $12.5 million, or 41%, to $17.6 million for the quarter ended March 31, 2023, primarily reflecting higher advertising and marketing expenses.

Liquidity and Capital Resources

The following table presents a summary of our cash flow activity for the periods set forth below (in thousands):

Quarter Ended

March 31,

2022

2021

Condensed Consolidated Statements of Cash Flows - Summary

Net cash used in operating activities

$
(31,747)

$
(18,026)

Net cash used in investing activities

(27,567)

(16,030)

Net cash provided by financing activities

2,816

22,175

Total

$
(56,498)

$
(11,881)


	Quarter Ended March 31,
Consolidated Statements of Cash Flows - Summary	2023		2022
Net cash provided by (used in) operating activities	$	13,156	$	(31,747)
Net cash used in investing activities		(45,624)		(27,567)
Net cash provided by financing activities		3,353		2,816	��
Foreign exchange difference		(488)		(538)
Total decrease in cash and cash equivalents	$	(29,603)	$	(57,036)

Our principal sources of liquidity ~~were~~are cash and cash equivalents, ~~comprised substantially of deposit accounts and money market funds, totaling $836.4 million, including restricted cash of $3.8~~which totaled $888.6 million as of March 31, ~~2022. Additionally, we had short-term marketable securities of $2.5 million as of March 31, 2022.~~2023.

We believe that our existing cash and cash equivalents ~~and short-term investments~~ will be sufficient to meet our working capital, capital expenditure, and contractual obligation needs for at least the next 12 months. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, number of visits, the timing and extent of spending to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced services offerings, the continuing market acceptance of telehealth, and our debt service obligations. We may in the future enter into arrangements to acquire or invest in complementary businesses, services, technologies, and intellectual property rights. We may be required to seek additional equity or debt financing to fund working capital, capital expenditures and acquisitions, and to settle debt obligations. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all, which would adversely affect our business, financial condition and results of operations.

Historically, we have financed our operations primarily through sales of equity securities, debt issuance, and bank borrowings.

See Note ~~11,~~10. “Convertible Senior Notes” of the notes to the condensed consolidated financial statements ~~in this Quarterly Report on Form 10-Q~~ for additional information on ~~the Notes.~~our convertible senior notes.

We routinely enter into contractual obligations with third parties to provide professional services, licensing, and other products and services in support of our ongoing business. The current estimated cost of these contracts is not expected to be significant to our liquidity and capital resources based on contracts in place as of March 31, ~~2022.~~2023.

Cash ~~Used in~~from Operating Activities

~~For the three months ended March 31, 2022 cash~~Cash flows ~~used in~~provided by operating activities ~~consisted~~consist of net loss adjusted for certain non-cash items and changes in assets and liabilities. ~~Cash used in~~Net cash provided by operating activities was ~~$31.7~~$13.2 million for the ~~three months~~quarter ended March 31, ~~2022~~2023 compared to net cash used in operating activities of ~~$18.0~~$31.7 million for the ~~three months~~quarter ended March 31, ~~2021.~~2022. The ~~year-over-year higher outflow~~year-

Table of Contents

over-year improvement was primarily driven by ~~an increase~~growth in ~~accounts receivable and prepaid expenses, substantially related to software licenses and deferred device costs,~~the business as well as lower incentive compensation payments and higher ~~bonus and payroll tax payments.~~interest income.

Our primary uses of cash from operating activities are for the payment of cash compensation, provider fees, engagement marketing, ~~D2C~~direct-to-consumer digital and media advertising, inventory, insurance, technology costs, interest expense and acquisition, integration, and transformation costs. Historically, our cash compensation is at its highest level in the first quarter when we pay discretionary employee compensation related to the previous fiscal year.

Cash ~~Used in~~from Investing Activities

Cash used in investing activities was $45.6 million for the quarter ended March 31, 2023, and $27.6 million for the ~~three months~~quarter ended March 31, 2022. ~~Cash used in investing activities consisted of capital expenditures totaling $3.9 million and~~Amounts for both periods primarily relate to payments for capitalized software development costs ~~of $26.9 million.~~associated with ongoing projects and services to continuously improve and optimize our products and services.

Cash used in investing activities was $16.0 million for the three months ended March 31, 2021. Cash used in investing activities consisted of the acquisition of businesses of $55.9 million, investment in capital expenditures totaling

~~Table of Contents~~

~~$2.1 million and capitalized software development costs of $11.1 million, partially offset by proceeds from short-term marketable securities of $50.0 million.~~

Cash ~~Provided by~~from Financing Activities

Cash provided by financing activities for the ~~three months~~quarter ended March 31, 2023 was $3.4 million, primarily consisting of the proceeds from the exercise of employee stock options, proceeds withheld from participants in the employee stock purchase plan, partially offset by net payments against advances from financing companies.

Cash provided by financing activities for the quarter ended March 31, 2022 was $2.8 million. Cash provided by financing activities primarily consisted of ~~$3.6 million of~~the proceeds from the exercise of employee stock options, ~~$3.7 million of~~ proceeds withheld from participants in the employee stock purchase plan, ~~and $2.2 million of proceeds from advances from financing companies,~~ partially offset by ~~($3.9) million from a~~ net ~~change in~~ payments ~~against advances from financing companies and other items of ($2.9) million.~~

Cash provided by financing activities for the three months ended March 31, 2021 was $22.2 million. Cash provided by financing activities primarily consisted of $11.9 million of proceeds from the exercise of employee stock options, $8.6 million of proceeds withheld from participants in the employee stock purchase plan, $4.8 million of proceeds from advances from financing companies, $1.2 million of timing associated with net cash proceeds for tax withholding for stock-based compensation and redemption of 2022 Notes, and $4.1 million from a net change in payments from customers against advances from financing companies.

~~Recently Adopted Accounting Standards~~

The following is a reconciliation of net cash provided by operating activities to free cash flow (in thousands, unaudited):


	Quarter Ended March 31,
	2023		2022
Net cash provided by (used in) operating activities	$	13,156	$	(31,747)
Capital expenditures		(2,363)		(3,913)
Capitalized software		(43,261)		(26,918)
Free Cash Flow	$	(32,468)	$	(62,578)

In August 2020, the financial accounting standards board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06—"Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by eliminating the conversion option separation model for convertible debt that can be settled in Free cash and by eliminating the measurement model for beneficial conversion features. Convertible instruments that continue to be subject to separation models are (1) those with conversion options that are required to be accounted for as bifurcated derivatives and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. This ASU also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards.

We adopted ASU 2020-06 as of January 1, 2022, under the modified retrospective transition method, and accordingly, our prior period financial statements were not restated. Upon adoption of ASU 2020-06, the conversion feature of our convertible senior notes is no longer reported as a component of equity. Instead, the previously-separated equity component is now combined with the liability component, thereby eliminating the amortization of the debt discount arising from the conversion option separation model. As such, we currently anticipate a reduction of ~~approximately $58~~outflow was $32.5 million ~~in non-cash interest to be recorded on our convertible senior notes~~ for the ~~year~~quarter ended ~~December~~March 31, ~~2022,~~2023, as compared to $62.6 million for the ~~year~~quarter ended ~~December~~March 31, ~~2021.~~ ~~To reflect~~2022. The year-over-year increase was substantially driven by growth in the ~~adoption of ASU 2020-06, we recorded an increase to convertible senior notes of $306.3 million~~business, lower incentive compensation payments, and ~~decreases to additional paid-in capital, accumulated deficit and net deferred tax liabilities of $363.7 million, $72.7 million, and $15.3~~higher interest income, partially offset by higher capitalized software costs. ~~million,~~

~~respectively, as of January 1, 2022.~~

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk and Foreign Exchange Risk

Cash equivalents that are subject to interest rate volatility represent our principal market risk. We do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates as our ~~Notes and Livongo Notes~~convertible senior notes bear fixed interest rates. We do not enter into investments for trading or speculative purposes.

We operate our business primarily within the U.S. which accounts for approximately ~~87%~~86% of our revenues. We have not utilized hedging strategies with respect to our foreign exchange exposure as we believe it is not expected to have a material impact on our condensed consolidated financial statements.

Concentrations of Risk and Significant Clients

~~The Company’s~~

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents ~~short-term investments~~ and accounts receivable. ~~The Company deposits its~~We deposit our cash with financial institutions in the U.S. and in foreign countries, however, our deposits, at times, may exceed federally insured limits. Our cash equivalents are primarily invested in institutional money market funds.

Table of Contents

institutions in the U.S. and in foreign countries, however, its deposits, at times, may exceed federally insured limits. The Company’s short-term investment balance as of March 31, 2022 and December 31, 2021 consisted primarily of a domestic certificate of deposit with an original maturity of one year.

No Client represented over 10% of revenues for the quarters quarter ended March 31, ~~2022~~2023 or ~~2021.~~2022.

No Client represented over 10% of accounts receivable at March 31, ~~2022~~2023 or December 31, ~~2021.~~2022.

Item 4. Controls and Procedures

Management’s Report on Internal Control over Financial Reporting

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of March 31, ~~2022,~~2023, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

During 2022, we implemented a new ERP system for selected entities and transaction types included within our consolidated financial statements. As a result of this ERP system implementation, we revised certain existing internal controls, processes, and procedures. There are inherent risks in implementing an ERP system and, accordingly, we will continue to evaluate the design and operating effectiveness of these controls.

Other than this ERP system implementation, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) ~~occurred~~ during the quarter ended March 31, ~~2022~~2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are subject to legal proceedings, claims and litigation arising in the ordinary course of our business. Descriptions of certain legal proceedings to which we are a party are contained in Note ~~13,~~16. “Legal Matters”, to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q and are incorporated by reference herein.

Item 1A. Risk Factors

For a discussion of potential risks and uncertainties related to our Company see the information in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the “Special Note Regarding Forward-Looking Statements” section in Part I, Item 2, of this Quarterly Report on Form 10-Q.

Table of Contents

Item 6. Exhibits

Exhibit

Index

Incorporated by Reference
Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed
Herewith

3.1

Sixth Amended and Restated Certificate of Incorporation of Teladoc Health, Inc.

8-K

001-37477

3.1

5/31/17

3.2

Certificate of Amendment of Sixth Amended and Restated Certificate of Incorporation of Teladoc, Inc.

8-K

001-37477

3.1

6/1/18

3.3

Second Certificate of Amendment of Sixth Amended and Restated Certificate of Incorporation of Teladoc Health, Inc.

8-K

001-37477

3.1

8/10/18

3.4

Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation of Teladoc Health, Inc.

8-K

001-37477

3.1

10/30/20

3.5

Fifth Amended and Restated Bylaws of Teladoc Health, Inc.

8-K

001-37477

3.1

2/19/21

10.1

Form of Performance Restricted Stock Unit Agreements under the Teladoc Health, Inc. 2015 Incentive Award Plan.

*

10.2

Executive Severance Agreement, dated July 15, 2015, by and between Teladoc Health, Inc. and Andrew Turitz, as amended by Amendment No. 1 to Executive Severance Agreement, dated October 29, 2019, by and between Teladoc Health, Inc. and Andrew Turitz.

10-K

001-37477

10.34

2/26/20

31.1

Chief Executive Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*

31.2

Chief Financial Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

*

32.1

Chief Executive Officer—Certification pursuant to Rule13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

**

32.2

Chief Financial Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

**

~~Table of Contents~~

~~101.INS~~

~~XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the~~

~~Inline XBRL document.~~

~~101.SCH~~

~~XBRL Taxonomy Extension Schema Document.~~

~~101.CAL~~

~~XBRL Taxonomy Calculation Linkbase Document.~~

~~101.DEF~~

~~XBRL Definition Linkbase Document.~~

~~101.LAB~~

~~XBRL Taxonomy Label Linkbase Document.~~

~~101.PRE~~

~~XBRL Taxonomy Presentation Linkbase Document.~~

~~104~~

~~Cover Page Interactive Data File – The Cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document~~

Incorporated by Reference

Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed
Herewith

3.1

Seventh Amended and Restated Certificate of Incorporation of Teladoc Health, Inc.

8-K

001-37477

3.1

6/2/22

3.2

Sixth Amended and Restated Bylaws of Teladoc Health, Inc.

8-K

001-37477

3.2

6/2/22

31.1

Chief Executive Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Chief Financial Officer—Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Chief Executive Officer—Certification pursuant to Rule13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Chief Financial Officer—Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the

Inline XBRL document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Calculation Linkbase Document.

101.DEF

XBRL Definition Linkbase Document.

101.LAB

XBRL Taxonomy Label Linkbase Document.

101.PRE

XBRL Taxonomy Presentation Linkbase Document.

104

Cover Page Interactive Data File – The Cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

* Filed herewith.

** Furnished herewith.

3534

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TELADOC HEALTH, INC.

Date: May 2, ~~2022~~2023	By:	/s/ JASON GOREVIC
	Name:	Jason Gorevic
	Title:	Chief Executive Officer

Date: May 2, ~~2022~~2023	By:	/s/ MALA MURTHY
	Name:	Mala Murthy
	Title:	Chief Financial Officer

3635


Testing dates	Discount Rate	Peer Group Revenue Multiples (current year/subsequent year)	% Excess of Reporting Unit Fair Value over Carrying Value
December 1, 2021	10.5%	7.0x/5.5x	15.0%
March 31, 2022	12.0%	3.0x/2.5x	0% post impairment


	March 31, 2022
	Level 1		Level 2		Total
Cash and cash equivalents	$	836,444	$	0	$	836,444
Short-term investments	$	0	$	2,544	$	2,544


		Quarter Ended
		March 31,
2027 Notes:		2022		2021
Contractual interest expense	$	3,125		$	3,125
Amortization of debt discount		831			9,059
Total	$	3,956		$	12,184
Effective interest rate		0.8	%		3.4	%

	Quarter Ended
	March 31,
2025 Notes:		2022		2021
Contractual interest expense	$	3		$	814
Amortization of debt discount		1			2,719
Total	$	4		$	3,533
Effective interest rate		0.9	%		3.9	%

	Quarter Ended
	March 31,
Livongo Notes:		2022		2021
Contractual interest expense	$	1,203		$	1,203
Amortization of debt discount		0			4,734
Total	$	1,203		$	5,937
Effective interest rate		0	%		5.2	%

	Quarter Ended
	March 31,
2022 Notes:		2022		2021
Contractual interest expense	$	0		$	104
Amortization of debt discount		0			316
Total	$	0		$	420
Effective interest rate		0	%		9.6	%


	Quarter Ended March 31,				Year over Year Growth
	2022		2021			Variance	%
Revenue	$	565,350	$	453,675	$	111,675	25	%
Expenses:
Cost of revenue (exclusive of depreciation and amortization, which is shown separately below)		187,025		145,959		41,066	28	%
Operating expenses:
Advertising and marketing		133,600		89,439		44,161	49	%
Sales		58,329		64,793		(6,464)	(10)	%
Technology and development		87,412		78,008		9,404	12	%
General and administrative		104,923		105,172		(249)	0	%
Acquisition, integration, and transformation costs		4,507		6,323		(1,816)	(29)	%
Depreciation and amortization		58,933		48,659		10,274	21	%
Goodwill impairment		6,600,000		0		6,600,000	N/M
Total expenses		7,234,729		538,353		6,696,376	N/M
Loss from operations		(6,669,379)		(84,678)		(6,584,701)	N/M
Loss on extinguishment of debt		0		11,459		(11,459)	(100)	%
Other income, net		(724)		(5,652)		4,928	(87)	%
Interest expense, net		5,480		22,125		(16,645)	(75)	%
Net loss before taxes		(6,674,135)		(112,610)		(6,561,525)	N/M
Income tax expense		388		87,039		(86,651)	(100)	%
Net loss	$	(6,674,523)	$	(199,649)	$	(6,474,874)	N/M
Net loss per share, basic and diluted	$	(41.58)	$	(1.31)	$	(40.27)	N/M

EBITDA (1)	$	(10,446)	$	(36,019)	$	25,573	(71)	%
Adjusted EBITDA (1)	$	54,497	$	56,604	$	(2,107)	(4)	%